var title_f15_26_15776="Osmotic diarrhea child";
var content_f15_26_15776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluation of a child with osmotic diarrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 599px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This algorithm shows a typical diagnostic pathway for many patients in this age group. Other sequences of testing may be appropriate in some cases.",
"    <div class=\"footnotes\">",
"     * As defined by Rome III criteria.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Refer to topic review on lactose intolerance for interpretation of lactose breath testing.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15776=[""].join("\n");
var outline_f15_26_15776=null;
var title_f15_26_15777="Decidual cyst";
var content_f15_26_15777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Decidual cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal view of a retroverted uterus shows a tiny fluid collection (arrowhead) located close to the endometrial-myometrial junction, consistent with a decidual cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15777=[""].join("\n");
var outline_f15_26_15777=null;
var title_f15_26_15778="Obesity risk algorithm";
var content_f15_26_15778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    A systematic approach to management based on BMI and other risk factors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 656px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:i. Copyright &copy; 2000 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15778=[""].join("\n");
var outline_f15_26_15778=null;
var title_f15_26_15779="Kidney stones in children";
var content_f15_26_15779=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Kidney stones in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/26/15779/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15779/contributors\" id=\"au1538\">",
"       Jodi Smith, MD, MPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15779/contributors\" id=\"au839\">",
"       F Bruder Stapleton, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/26/15779/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15779/contributors\" id=\"se6305\">",
"       Tej K Mattoo, MD, DCH, FRCP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/26/15779/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15779/contributors\" id=\"de7255\">",
"       Melanie S Kim, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?15/26/15779?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Kidney stones (also called nephrolithiasis or urolithiasis) develop when a collection of minerals or other material form a small \"stone.\" The stone can cause pain, block the flow of urine, and rarely cause long-term kidney problems if it is not recognized and treated promptly. Fortunately, most children who develop kidney stones recover without any long-term complications.",
"    </p>",
"    <p>",
"     Stones are less common in children than in adults. Most children who develop kidney stones have an underlying condition that increases their risk of stones, although some children develop a stone for unknown reasons.",
"    </p>",
"    <p>",
"     A discussion of kidney stones in adults is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"      \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about kidney stones in children is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38552?source=see_link\">",
"      \"Acute management of nephrolithiasis in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW KIDNEY STONES DEVELOP",
"     </span>",
"    </p>",
"    <p>",
"     The urinary tract is composed of two kidneys and ureters, a bladder, and a urethra (",
"     <a class=\"graphic graphic_figure graphicRef65630 \" href=\"UTD.htm?14/27/14769\">",
"      figure 1",
"     </a>",
"     ). A kidney stone usually forms when substances that are normally found in the urine, such as calcium, oxalate, cystine, or uric acid, are at high levels. However, in some children, stones can also form if these substances are at normal levels. Knowing what the stone is made of is important in deciding which treatment to use (see",
"     <a class=\"local\" href=\"#H13\">",
"      'Stone testing'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     The substances form crystals, which become anchored in the kidney and gradually increase in size, forming a kidney stone. Stones that are very small (less than 5 millimeters (0.2 inches)) can usually pass on their own, while larger stones usually require treatment.",
"    </p>",
"    <p>",
"     A kidney stone moves through the urinary tract and, if it is small enough, it will be passed in the urine. A larger stone can become stuck within the urinary tract, causing pain and sometimes blocking the flow of urine.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      KIDNEY STONE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptoms of kidney stones include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pain in the belly or back (",
"       <a class=\"graphic graphic_figure graphicRef54658 \" href=\"UTD.htm?12/35/12848\">",
"        figure 2",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Blood in the urine (hematuria)",
"      </li>",
"      <li>",
"       Nausea or vomiting",
"      </li>",
"      <li>",
"       Needing to rush to the bathroom to urinate",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, some children, particularly young children, do not have any symptoms, and the kidney stone is found when an imaging test (like an X-ray) is done for another reason.",
"    </p>",
"    <p>",
"     Some kidney stone symptoms are similar to those of a bladder infection (also called a urinary tract infection). Your child's doctor or nurse will need to perform an exam and do some testing to know what is causing the symptoms. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"      \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      KIDNEY STONE RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Certain factors can increase a child's risk of developing kidney stones. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=see_link\">",
"      \"Epidemiology of and risk factors for nephrolithiasis in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       History of kidney stones &ndash; Children who have had a kidney stone in the past have the highest risk of developing a stone in the future. Preventive measures can decrease the risk of developing a stone in the future. (See",
"       <a class=\"local\" href=\"#H11\">",
"        'Kidney stone prevention'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Not drinking enough &ndash; The amount of fluids a child drinks directly affects the amount of urine the body makes. Drinking a small amount of fluids means that the kidneys make a small amount of urine, which increases the concentration of stone-forming substances in the urine. Drinking more fluids can reduce the risk of recurrent stones. (See",
"       <a class=\"local\" href=\"#H14\">",
"        'Drink more fluids'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Ketogenic diet &ndash; Diets that include a very small amount of carbohydrates, called ketogenic diets, can increase the risk of developing kidney stones. Ketogenic diets are sometimes used to treat seizure disorders. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?19/5/19540?source=see_link\">",
"        \"Patient information: Treatment of seizures in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Cystic fibrosis &ndash; Children with cystic fibrosis are at higher risk of developing kidney stones.",
"      </li>",
"      <li>",
"       Urinary tract abnormalities &ndash; Having congenital (from birth) abnormalities in the kidneys, ureters, or bladder can increase the risk of developing a kidney stone.",
"      </li>",
"      <li>",
"       Medicines &ndash; Some medicines increase the risk of forming crystals in the urine. These include furosemide (Lasix), acetazolamide (Diamox), and allopurinol (Aloprim, Zyloprim).",
"      </li>",
"      <li>",
"       Inherited disorders &ndash; Several uncommon inherited disorders can increase a child's risk of developing kidney stones. Testing for these disorders might be recommended.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      KIDNEY STONE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If your child has symptoms of a kidney stone, he or she should see a doctor or nurse as soon as possible. The doctor or nurse will do an exam and order urine testing.",
"    </p>",
"    <p>",
"     If a stone is likely, based on the exam and urine tests, he or she will order an imaging test, like a CT scan, ultrasound, or X-ray. The imaging test can show the exact size and location of the stone, which will help to guide treatment. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13623?source=see_link\">",
"      \"Clinical features and diagnosis of nephrolithiasis in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      KIDNEY STONE TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Treatment at home",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the stone is small, pain is manageable, and the child is otherwise healthy, it is often possible to treat the stone at home. Stones smaller than 5 millimeters (0.2 inches) often pass on their own without treatment.",
"    </p>",
"    <p>",
"     You can treat your child's pain with a non-prescription medicine like ibuprofen (sold as Advil&reg;, Motrin&reg;, and store brands). The child should also drink more fluids than usual to help flush the stone out. (See",
"     <a class=\"local\" href=\"#H14\">",
"      'Drink more fluids'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     You will need to strain your child's urine for a few days, until the stone passes. Urine strainers are available from most hospital supply stores. You place the strainer under the toilet seat. If you cannot find a urinary strainer, you can use a toilet hat covered with cheese cloth or a fine mesh sheet. A fish net used for home aquariums is also a good alternative.",
"    </p>",
"    <p>",
"     If the child passes a stone or stone fragment, save it in a clean container. A lab can analyze the stone to determine the type, which can guide treatment. After the child passes the stone, a follow-up test (usually ultrasound) might be done to confirm that the stone is gone and that no other stones or stone fragments are left.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Hospital treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some cases, the child will need to be hospitalized for treatment. The two most common reasons for hospitalization are that:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The stone is blocking the urinary tract, preventing the normal flow of urine. If the blockage is not treated quickly, it can cause permanent damage to the kidneys.",
"      </li>",
"      <li>",
"       The child's pain cannot be controlled because it is severe or because the child is vomiting.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In the hospital, the child will be given intravenous (IV) pain medications and IV fluids. If the stone is small, this treatment may be continued for several days, until the stone passes. During this time, the location of the stone is usually monitored with ultrasound. The child's urine will be strained to recover any stone or stone fragments that pass.",
"    </p>",
"    <p>",
"     However, stones larger than 9 or 10 millimeters (about half an inch) rarely pass on their own and generally require treatment. Other reasons for treatment include severe pain and if the stone is blocking the urinary tract.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Treatments to eliminate the stone",
"     </span>",
"     &nbsp;&mdash;&nbsp;One or more treatments can be used to eliminate a kidney stone. Shock wave lithotripsy is the first-line treatment in most cases.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Shock wave lithotripsy &ndash; Shock wave lithotripsy is the treatment of choice for kidney stone in many children. Lithotripsy is done by directing a high-energy shock wave toward the stone. The energy causes the stone to break into fragments that can be passed. The procedure takes about 20 minutes. Some, although not all, children are given anesthesia to prevent movement during the treatment.",
"       <br/>",
"       <br/>",
"       The success of lithotripsy depends, in part, on the size of the stone; larger stones are more difficult to break up and sometimes need more than one treatment. It can take three months after lithotripsy for all of the stone fragments to pass.",
"      </li>",
"      <li>",
"       Percutaneous nephrolithotomy &ndash; Large stones or stones that do not break up with lithotripsy will require a minimally invasive surgical procedure to remove the stone. During the procedure, small instruments are passed through the skin (percutaneously) into the kidney to remove the stone. The child is given anesthesia before the procedure to prevent pain.",
"      </li>",
"      <li>",
"       Ureteroscopy &ndash; Ureteroscopy is a procedure that can be done if the stone is in the middle and lower portion of the ureter (",
"       <a class=\"graphic graphic_figure graphicRef65630 \" href=\"UTD.htm?14/27/14769\">",
"        figure 1",
"       </a>",
"       ). A doctor passes a small instrument through the urethra and bladder, into the ureter. The instrument contains a camera and other instruments, which allows the doctor to see the stone. The stone can be removed or broken up into smaller pieces that can pass more easily.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Will my child have kidney problems in the future?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The chances of developing kidney stones, kidney damage, and other complications after a first kidney stone depend largely on the child's age at the time of the first stone and the underlying reason that the stone developed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      KIDNEY STONE PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Children who develop a kidney stone have a significant chance of developing stones in the future. Studies have estimated the chances to be between 30 and 65 percent [",
"     <a class=\"abstract\" href=\"UTD.htm?15/26/15779/abstract/1\">",
"      1",
"     </a>",
"     ]. However, a number of steps can decrease the chances of developing another stone. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/62/19432?source=see_link\">",
"      \"Prevention of recurrent nephrolithiasis in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Blood and urine tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a child has had a kidney stone, blood and urine tests are performed to identify factors that can increase the risk of future stones. Testing is not done until the child is at home, walking and playing normally, eating a normal diet, and has finished any treatment for urinary tract infection.",
"    </p>",
"    <p>",
"     You might be asked to collect your child's urine for 24 hours. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"      \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Stone testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the stone was passed and saved, it should be analyzed to determine the type of stone. Based on what the stone is made of, one or more treatments might help to reduce the risk of future stones (see",
"     <a class=\"local\" href=\"#H15\">",
"      'Treatment'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Drink more fluids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Drinking more fluids can help to decrease the risk of forming all types of kidney stones. The goal is to increase the amount of urine that flows through the kidneys and ureters and to lower the concentration of substances that promote stone formation.",
"    </p>",
"    <p>",
"     To gauge how much more fluid the child should be drinking, your doctor or nurse might recommend measuring how much urine the child passes over the course of 24 hours. The child should drink more if he or she makes less than this amount of urine per 24 hours.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Infants &ndash; 750 mL or more (25 ounces or three cups)",
"      </li>",
"      <li>",
"       Children younger than five years of age &ndash; 1000 mL or more (33 ounces or four cups)",
"      </li>",
"      <li>",
"       Children between five and ten years of age &ndash; 1500 mL or more (50 ounces or six cups)",
"      </li>",
"      <li>",
"       Children greater than 10 years of age &ndash; 2000 mL or more (66 ounces or eight cups)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;One or more treatments might be recommended to decrease the risk of developing another kidney stone in the future. The best treatment depends on what minerals or other materials were found in the first stone (see",
"     <a class=\"local\" href=\"#H13\">",
"      'Stone testing'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Calcium",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children with increased levels of calcium in the urine should drink more fluids and make some changes in their diet:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Eat a low-sodium diet (",
"       <a class=\"graphic graphic_figure graphicRef73775 \" href=\"UTD.htm?3/46/3816\">",
"        figure 3",
"       </a>",
"       and",
"       <a class=\"graphic graphic_table graphicRef53813 \" href=\"UTD.htm?16/1/16413\">",
"        table 1",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Get the right amount of calcium from foods and drinks. The amount of calcium in selected foods is provided in the following table (",
"       <a class=\"graphic graphic_table graphicRef67824 \" href=\"UTD.htm?28/58/29611\">",
"        table 2",
"       </a>",
"       ). Consuming too much calcium in foods and drinks is not recommended. However, the child should not stop eating foods and drinks with calcium because calcium is important in building strong bones.",
"       <br/>",
"       <br/>",
"       The \"right\" amount of calcium depends on the child's age:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       500",
"       <span class=\"nowrap\">",
"        mg/day",
"       </span>",
"       for children one to three years",
"      </li>",
"      <li>",
"       800",
"       <span class=\"nowrap\">",
"        mg/day",
"       </span>",
"       for children four to eight years",
"      </li>",
"      <li>",
"       1300",
"       <span class=\"nowrap\">",
"        mg/day",
"       </span>",
"       for children nine years and older",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid calcium and vitamin D supplements",
"      </li>",
"      <li>",
"       Eat potassium-rich foods (fresh fruits and vegetables)",
"      </li>",
"      <li>",
"       If urine calcium levels are still high after three to six months of these changes, a medicine might be recommended",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Oxalate",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children who have high levels of oxalate in the urine should:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Drink more fluids",
"      </li>",
"      <li>",
"       Avoid vitamin C supplements",
"      </li>",
"      <li>",
"       Avoid foods that contain large amounts of oxalate, including beet and turnip greens, rhubarb, strawberries, star fruit, sweet potatoes, wheat bran, tea, cocoa, pepper, chocolate, parsley, beets, spinach, dill, nuts, and citrus juices",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Urate",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children with increased levels of urate in the urine should drink more fluids. Some children will be given a treatment to increase the pH of the urine (potassium citrate or potassium carbonate).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Cystine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children with high levels of cystine in the urine should drink more fluids. Some children will be given a medicine that reduces the acidity (ie, increases the pH) of the urine (potassium citrate or potassium carbonate).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Low citrate",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children who have a low level of citrate in the urine are usually given a treatment to increase citrate levels (potassium citrate or potassium bicarbonate).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Struvite",
"     </span>",
"     &nbsp;&mdash;&nbsp;Struvite stones usually develop because of a urinary tract infection. Preventing future urinary tract infections can help to prevent struvite stones. This is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"      \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Complementary and alternative therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are no data about the safety or benefit of complementary and alternate therapies for kidney stones in children (including herbs, homeopathy, acupuncture, and others). We do not recommend these therapies because they are unproven.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a first kidney stone, the child's doctor or nurse might recommend an imaging test (like ultrasound) to monitor for new stones. This is especially important for children who are at high risk of kidney stones.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6600152\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6600160\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=see_link\">",
"      Patient information: Kidney stones in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/38/27234?source=see_link\">",
"      Patient information: Kidney stones in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6600178\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Basic content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6600186\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?15/26/15779/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?15/26/15779?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15779/abstract/1\">",
"      Schwarz RD, Dwyer NT. Pediatric kidney stones: long-term outcomes. Urology 2006; 67:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15779/abstract/2\">",
"      Muslumanoglu AY, Tefekli A, Sarilar O, et al. Extracorporeal shock wave lithotripsy as first line treatment alternative for urinary tract stones in children: a large scale retrospective analysis. J Urol 2003; 170:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15779/abstract/3\">",
"      Shokeir AA, Sheir KZ, El-Nahas AR, et al. Treatment of renal stones in children: a comparison between percutaneous nephrolithotomy and shock wave lithotripsy. J Urol 2006; 176:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15779/abstract/4\">",
"      McLorie GA, Pugach J, Pode D, et al. Safety and efficacy of extracorporeal shock wave lithotripsy in infants. Can J Urol 2003; 10:2051.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f15_26_15779=[""].join("\n");
var outline_f15_26_15779=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW KIDNEY STONES DEVELOP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           KIDNEY STONE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           KIDNEY STONE RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           KIDNEY STONE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           KIDNEY STONE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           KIDNEY STONE PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\" title=\"figure 1\">",
"           Urinary anatomy pedi PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/35/12848\" title=\"figure 2\">",
"           Flank pain child PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/46/3816\" title=\"figure 3\">",
"           Low sodium diet 1 PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?16/1/16413\" title=\"table 1\">",
"           Low sodium diet 2 PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/58/29611\" title=\"table 2\">",
"           Foods with calcium PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f15_26_15780="Contents: General pediatrics";
var content_f15_26_15780=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       General pediatrics",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			General pediatrics",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Calculators",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13697\">",
"           Calculator: Apgar score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9463\">",
"           Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9751\">",
"           Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36070\">",
"           Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/60/35782\">",
"           Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/49/43796\">",
"           Calculator: Body mass index for boys (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12596\">",
"           Calculator: Body mass index for girls (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/47/22262\">",
"           Calculator: CDC height for age percentiles for boys (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/7/22646\">",
"           Calculator: CDC height for age percentiles for girls (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/50/35619\">",
"           Calculator: CDC weight for height percentiles for boys (77 to 121 cm tall)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2644\">",
"           Calculator: CDC weight for height percentiles for girls (77 to 121 cm tall)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/25/16788\">",
"           Calculator: CDC/NCHS infant head circumference for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34339\">",
"           Calculator: CDC/NCHS infant length for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/10/162\">",
"           Calculator: CDC/NCHS infant weight for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/53/6997\">",
"           Calculator: CDC/NCHS infant weight for length percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24193\">",
"           Calculator: Glomerular filtration rate estimate by Schwartz formula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/60/8129\">",
"           Calculator: Maintenance fluid calculation for children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30769\">",
"           Calculator: Mid-parental target height prediction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/63/5109\">",
"           Calculator: Newborn hyperbilirubinemia assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9860\">",
"           Calculator: PELD score for end-stage liver disease (patients less than 12 years old)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36485\">",
"           Calculator: WHO Assessment of Malnutrition in Boys 0 to 2 Years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30213\">",
"           Calculator: WHO Assessment of Malnutrition in Boys 2 to 5 years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/1/36885\">",
"           Calculator: WHO Assessment of Malnutrition in Girls 0 to 2 Years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/48/30469\">",
"           Calculator: WHO Assessment of Malnutrition in Girls 2 to 5 years Old",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27241\">",
"           Approach to chest pain in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Care of the hospitalized child",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33798\">",
"           Auxiliary services in pediatrics",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Child abuse and neglect",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/5/35927\">",
"           Child abuse: Social and medicolegal issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18408\">",
"           Child neglect and emotional abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31097\">",
"           Childhood exposure to intimate partner violence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/27/23990\">",
"           Differential diagnosis of suspected child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/23/11641\">",
"           Differential diagnosis of the orthopedic manifestations of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35258\">",
"           Evaluation of sexual abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/15/11510\">",
"           Management and sequelae of sexual abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/16/36104\">",
"           Munchausen syndrome by proxy (medical child abuse)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/19/24890\">",
"           Physical abuse in children: Diagnostic evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/54/26473\">",
"           Physical abuse in children: Epidemiology and clinical manifestations",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Child care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/20/8520\">",
"           Adoption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/5/27737\">",
"           Children with special health care needs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/13/16602\">",
"           Comprehensive health care for children in foster care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/15/43255\">",
"           Developmental and behavioral implications for military children with deployed parents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/58/32679\">",
"           Support services for the care of chronically ill children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ear; nose; oropharynx; and larynx",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/35/8760\">",
"           Acute otitis media in children: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29642\">",
"           Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/0/21514\">",
"           Acute otitis media in children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41417\">",
"           Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12823\">",
"           Cerumen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35397\">",
"           Ear barotrauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6615\">",
"           Jaw fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22153\">",
"           Otitis media with effusion (serous otitis media) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/61/43992\">",
"           Retropharyngeal infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/37/27224\">",
"           Symptomatic relief of sore throat in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Environmental influences",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31097\">",
"           Childhood exposure to intimate partner violence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/24/394\">",
"           Childhood lead poisoning: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/47/11001\">",
"           Childhood lead poisoning: Exposure and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/5/21594\">",
"           Childhood lead poisoning: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/27/16823\">",
"           Information and educational resources for occupational and environmental health issues in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/51/13114\">",
"           Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/13/14553\">",
"           Overview of occupational and environmental health",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/36/14921\">",
"           Prevention of firearm injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40343\">",
"           Television and media violence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastroenterology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11593\">",
"           Causes of acute abdominal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/63/15354\">",
"           Constipation in children: Etiology and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/9/44182\">",
"           Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/17/1306\">",
"           Evaluation of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6984\">",
"           Management of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genetic diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/15/26874\">",
"           Clinical features and diagnosis of Down syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13224\">",
"           Management of Down syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Growth and development",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/54/3946\">",
"           Etiology and evaluation of macrocephaly in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/51/36665\">",
"           Etiology and evaluation of microcephaly in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/40/42633\">",
"           Normal growth patterns in infants and prepubertal children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/25/1434\">",
"           Normal puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/18/38185\">",
"           School readiness",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gynecologic issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/6/25703\">",
"           Clinical features and diagnosis of candidemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/11/12473\">",
"           Diagnosis and management of congenital anomalies of the vagina",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/19/43316\">",
"           Gynecologic examination of the newborn and child",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/47/31481\">",
"           Overview of Candida infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26072\">",
"           Vulvovaginal complaints in the prepubertal child",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hearing",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12823\">",
"           Cerumen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35397\">",
"           Ear barotrauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/38/19050\">",
"           Etiology of hearing impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44344\">",
"           Evaluation of hearing impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27865\">",
"           Screening the newborn for hearing loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/14/29927\">",
"           Treatment of hearing impairment in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Immunization",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/5/43097\">",
"           Allergic reactions to vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/36/21066\">",
"           Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/14/26857\">",
"           Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/10/13480\">",
"           Clinical trials of human papillomavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/27/34233\">",
"           Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/37/5722\">",
"           Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/37/601\">",
"           Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/32/23050\">",
"           Meningococcal vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/14/7402\">",
"           Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/52/17223\">",
"           Poliovirus vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42489\">",
"           Prevention of Haemophilus influenzae infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37289\">",
"           Prevention of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/17/19738\">",
"           Recommendations for the use of human papillomavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/62/40937\">",
"           Rotavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27946\">",
"           Seasonal influenza vaccination in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/61/19418\">",
"           Standard childhood vaccines: Parental hesitancy or refusal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39818\">",
"           Standard immunizations for children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26229\">",
"           The life cycle, natural history, and immunology of human papillomaviruses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23110\">",
"           Treatment of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/7/40057\">",
"           Vaccinia virus as the smallpox vaccine",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infectious diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/30/9706\">",
"           Approach to the child with fever of unknown origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33128\">",
"           Approach to the child with peripheral lymphadenopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/44/16074\">",
"           Bronchiolitis in infants and children: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/19/27962\">",
"           Bronchiolitis in infants and children: Treatment; outcome; and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30744\">",
"           Causes of peripheral lymphadenopathy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24346\">",
"           Clinical features and diagnosis of seasonal influenza in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33480\">",
"           Clinical features of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/54/22377\">",
"           Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24857\">",
"           Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/48/22278\">",
"           Epidemiology of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/63/38905\">",
"           Etiologies of fever of unknown origin in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8632\">",
"           Etiology and clinical manifestations of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37289\">",
"           Prevention of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31767\">",
"           Treatment and prevention of parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23110\">",
"           Treatment of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Injury prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11767\">",
"           Overview of pediatric injury prevention: Epidemiology; history; application",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40617\">",
"           Peer violence and violence prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13225\">",
"           Prevention of bicycle injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/52/12106\">",
"           Prevention of falls in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/36/14921\">",
"           Prevention of firearm injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/3/37944\">",
"           Prevention of poisoning in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intoxications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/57/2970\">",
"           Acute iron poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/62/15337\">",
"           Button and cylindrical battery ingestion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/24/394\">",
"           Childhood lead poisoning: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/47/11001\">",
"           Childhood lead poisoning: Exposure and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/5/21594\">",
"           Childhood lead poisoning: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/12/7367\">",
"           Classification of trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/10/29865\">",
"           Clinical manifestations and evaluation of potentially toxic plant ingestions in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37913\">",
"           Decontamination of poisoned children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/2/16426\">",
"           Food poisoning in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/27/16823\">",
"           Information and educational resources for occupational and environmental health issues in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/51/13114\">",
"           Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/60/43974\">",
"           Management of ibuprofen poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/21/22874\">",
"           Opioid intoxication in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nephrology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30584\">",
"           Evaluation of microscopic hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26262\">",
"           Evaluation of proteinuria in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/62/11237\">",
"           Anencephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35977\">",
"           Approach to the child with headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29209\">",
"           Clinical features of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41768\">",
"           Epidemiology and etiology of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/54/5994\">",
"           Hydrocephalus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/10/26793\">",
"           Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5257\">",
"           Intellectual disability (mental retardation) in children: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40887\">",
"           Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/37/15962\">",
"           Management and prognosis of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/3/18490\">",
"           Management of migraine headache in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/38/12906\">",
"           Minor head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/28/13770\">",
"           Overview of developmental coordination disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/62/33767\">",
"           Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/57/3991\">",
"           Primary (congenital) encephalocele",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/39/42616\">",
"           Breastfeeding: Parental education and support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/0/18441\">",
"           Dietary recommendations for toddlers, preschool, and school-age children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/12/14538\">",
"           Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42967\">",
"           Fast food for children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34631\">",
"           Food protein-induced proctitis/colitis and enteropathy of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/43/10938\">",
"           Introducing solid foods and vitamin and mineral supplementation during infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18378\">",
"           Management of childhood obesity in the primary care setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/16/30985\">",
"           Management of failure to thrive (undernutrition) in children younger than two years",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/36/6727\">",
"           Nutritional composition of human milk for full-term infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/9/9369\">",
"           Organic foods and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/21/38233\">",
"           Poor weight gain in children older than two years of age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/4/8266\">",
"           Vegetarian diets for children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10762\">",
"           Retinopathy of prematurity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Oral health",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/42/39590\">",
"           Anatomy and development of the teeth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/55/19320\">",
"           Oral habits and orofacial development in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/26/33192\">",
"           Preventive dental care and counseling for infants and young children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26340\">",
"           Reduction of temporomandibular joint (TMJ) dislocation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30216\">",
"           Soft tissue lesions of the oral cavity in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Orthopedics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/26/8616\">",
"           Acquired torticollis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/4/42057\">",
"           Approach to the child with a limp",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/55/27511\">",
"           Approach to the child with bow-legs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/3/6199\">",
"           Approach to the child with knock-knees",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/45/19162\">",
"           Back pain in children and adolescents: Overview of causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/30/27113\">",
"           Clinical features and diagnosis of developmental dysplasia of the hip",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/23/11641\">",
"           Differential diagnosis of the orthopedic manifestations of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2679\">",
"           Evaluation of the child with back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12392\">",
"           Osgood-Schlatter disease (tibial tuberosity avulsion)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/21/16729\">",
"           Overview of hip pain in childhood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23706\">",
"           Overview of the causes of limp in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24581\">",
"           Patellar dislocations in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38532\">",
"           Radial head subluxation (nursemaid's elbow)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/42/23209\">",
"           Slipped capital femoral epiphysis (SCFE)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15208\">",
"           Splinting of musculoskeletal injuries",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/34/31272\">",
"           Apparent life-threatening event in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/18/1322\">",
"           Clinical manifestations and diagnosis of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24857\">",
"           Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8632\">",
"           Etiology and clinical manifestations of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/7/32889\">",
"           Evaluation of cervical spine injuries in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/44/35529\">",
"           Overview of complementary and alternative medicine in pediatrics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/20/37194\">",
"           Sudden infant death syndrome: Risk factors and risk reduction strategies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/0/36872\">",
"           Sudden unexpected infant death including SIDS: Initial management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/60/5066\">",
"           What's new in pediatrics",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Physical examination",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/19/43316\">",
"           Gynecologic examination of the newborn and child",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34280\">",
"           The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38471\">",
"           The pediatric physical examination: Chest and abdomen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/30/19943\">",
"           The pediatric physical examination: General principles and standard measurements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/59/11194\">",
"           The pediatric physical examination: HEENT",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/3/10295\">",
"           The pediatric physical examination: The perineum",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Primary care practice",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/35/20024\">",
"           Clinical practice guidelines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/22/14694\">",
"           Evidence-based medicine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/8/39047\">",
"           Preparing an office practice for pediatric emergencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychiatric disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/18/26922\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/61/32730\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/19/14650\">",
"           Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27241\">",
"           Approach to chest pain in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37354\">",
"           Chronic asthma in children younger than 12 years: Controller medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15319\">",
"           Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26010\">",
"           Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39670\">",
"           Chronic asthma in children younger than 12 years: Quick-relief agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/29/44505\">",
"           Etiology and management of hoarseness in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/2/2088\">",
"           Newborn screening",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/13/43225\">",
"           Screening tests in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27865\">",
"           Screening the newborn for hearing loss",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Speech and language",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30114\">",
"           Case illustrating the evaluation of speech and language impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/22/10599\">",
"           Emergent literacy including language development",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/29/44505\">",
"           Etiology and management of hoarseness in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/57/21399\">",
"           Etiology of speech and language disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26343\">",
"           Evaluation and treatment of speech and language disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4102\">",
"           Evaluation of the child with hoarseness",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/21/40281\">",
"           Etiology and evaluation of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7178\">",
"           Management of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/46/41705\">",
"           Neonatal circumcision: Risks and benefits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/9/7315\">",
"           Patient information: Bedwetting in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/57/15256\">",
"           Techniques for neonatal circumcision",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/44/17098\">",
"           Undescended testes (cryptorchidism) in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24346\">",
"           Clinical features and diagnosis of seasonal influenza in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33480\">",
"           Clinical features of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/54/22377\">",
"           Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24857\">",
"           Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/58/15272\">",
"           Epidemiology of influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/48/22278\">",
"           Epidemiology of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8632\">",
"           Etiology and clinical manifestations of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/29/40408\">",
"           Parvovirus B19 infection during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37289\">",
"           Prevention of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7050\">",
"           Respiratory syncytial virus infection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15640\">",
"           Respiratory syncytial virus infection: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38327\">",
"           Respiratory syncytial virus infection: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27946\">",
"           Seasonal influenza vaccination in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31767\">",
"           Treatment and prevention of parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23110\">",
"           Treatment of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-9FA24EF64E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_26_15780=[""].join("\n");
var outline_f15_26_15780=null;
var title_f15_26_15781="Contact dermatitis vulva";
var content_f15_26_15781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis of the vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rodriguez MI, Leclair CM. Benign vulvar dermatoses. Obstet Gynecol Surv 2012; 67:55. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15781=[""].join("\n");
var outline_f15_26_15781=null;
var title_f15_26_15782="ADA management patients DKA";
var content_f15_26_15782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Protocol for the management of adult patients with DKA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 787px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    DKA diagnostic criteria: serum glucose &gt;250 mg/dl, arterial pH &lt;7.3, serum bicarbonate &lt;18 mEq/l, and moderate ketonuria or ketonemia. Normal laboratory values vary; check local lab normal ranges for all electrolytes.",
"    <div class=\"footnotes\">",
"     IV: intravenous; SC: subcutaneous.",
"     <br>",
"      * After history and physical exam, obtain capillary glucose and serum or urine ketones (nitroprusside method). Begin one liter of 0.9 percent NaCl over one hour and draw arterial blood gases, complete blood count with differential, urinalysis, serum glucose, BUN, electrolytes, chemistry profile, and creatinine levels STAT. Obtain electrocardiogram, chest X-ray, and specimens for bacterial cultures, as needed.",
"      <br>",
"       &bull; Serum Na",
"       <sup>",
"        +",
"       </sup>",
"       should be corrected for hyperglycemia (for each 100 mg/dl glucose &gt;100 mg/dl, add 1.6 mEq to sodium value for corrected serum sodium value).",
"       <br>",
"        &Delta; An alternative IV insulin regimen is to give a continuous intravenous infusion of regular insulin at 0.14 units/kg/hour; at this dose, an initial intravenous bolus is not necessary.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy;2006 American Diabetes Association From Diabetes Care Vol 29, Issue 12, 2006. Modifications from Diabetes Care, Vol 32, Issue 7, 2009. Reprinted with permission from the American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15782=[""].join("\n");
var outline_f15_26_15782=null;
var title_f15_26_15783="Estropipate: Drug information";
var content_f15_26_15783=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Estropipate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/34/13862?source=see_link\">",
"    see \"Estropipate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F167767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Menopause, moderate-to-severe vasomotor symptoms:",
"     </b>",
"     Oral: Usual dosage range: 0.75-6 mg estropipate daily. Use the lowest dose and regimen that will control symptoms, and discontinue as soon as possible. Attempt to discontinue or taper medication at 3- to 6-month intervals. If a patient with vasomotor symptoms has not menstruated within the last &ge;2 months, start the cyclic administration arbitrarily. If the patient has menstruated, start cyclic administration on day 5 of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female hypogonadism:",
"     </b>",
"     Oral: 1.5-9 mg estropipate daily for the first 3 weeks, followed by a rest period of 8-10 days; use the lowest dose and regimen that will control symptoms. Repeat if bleeding does not occur by the end of the rest period. The duration of therapy necessary to product the withdrawal bleeding will vary according to the responsiveness of the endometrium. If satisfactory withdrawal bleeding does not occur, give an oral progestin in addition to estrogen during the third week of the cycle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female castration or primary ovarian failure:",
"     </b>",
"     Oral: 1.5-9 mg estropipate daily for the first 3 weeks of a theoretical cycle, followed by a rest period of 8-10 days; use the lowest dose and regimen that will control symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis prophylaxis (females):",
"     </b>",
"     Oral: 0.75 mg estropipate daily for 25 days of a 31-day cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrophic vaginitis or kraurosis vulvae:",
"     </b>",
"     Oral: 0.75-6 mg estropipate daily; administer cyclically. Use the lowest dose and regimen that will control symptoms; discontinue as soon as possible.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F167772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. A higher incidence of stroke and invasive breast cancer were observed in women &gt;75 years in a WHI substudy using conjugated equine estrogen.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15838038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F167773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.75 mg, 1.5 mg, 3 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe vasomotor symptoms associated with menopause; treatment of vulvar and vaginal atrophy; hypoestrogenism (due to hypogonadism, castration, or primary ovarian failure); osteoporosis (prophylaxis)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9958825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [oral]; Strength of recommendation - strong [oral]).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, hypertension, venous thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, mental depression, migraine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Chloasma, erythema multiforme, erythema nodosum, hemorrhagic eruption, hirsutism, loss of scalp hair, melasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast enlargement, breast tenderness, libido (changes in), increased thyroid-binding globulin, increased total thyroid hormone (T",
"     <sub>",
"      4",
"     </sub>",
"     ), increased serum triglycerides/phospholipids, increased HDL-cholesterol, decreased LDL-cholesterol, impaired glucose tolerance, hypercalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, bloating, cholecystitis, cholelithiasis, gallbladder disease, nausea, pancreatitis, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Alterations in frequency and flow of menses, changes in cervical secretions, endometrial cancer, increased size of uterine leiomyomata, vaginal candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Antithrombin III decreased; antifactor Xa decreased; fibrinogen levels increased; platelet aggregability increased; platelet count increased; porphyria aggravation; prothrombin and factors VII, VIII, IX, X increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Ocular: Contact lens intolerance, corneal curvature steepening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Carbohydrate intolerance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to estrogens or any component of the formulation; undiagnosed abnormal vaginal bleeding; DVT or PE (current or history of); active or recent (within 1 year) arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast; estrogen-dependent tumor; hepatic dysfunction or disease; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012).An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may also lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with severe hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of oral estrogen (with or without progestins) in this age group due to potential of increased risk of breast and endometrial cancers, and lack of proven cardioprotection and cognitive protection (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children. Prior to puberty, estrogens may cause premature closure of the epiphyses, premature breast development in girls or gynecomastia in boys. Vaginal bleeding and vaginal cornification may also be induced in girls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precaution:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis use: For use only in women at significant risk of osteoporosis and for who other nonestrogen medications are not considered appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vulvar and vaginal atrophy use: When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F167784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2B6 (minor), CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F167762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Routine use increases estrogen plasma concentrations and risk of breast cancer; avoid ethanol. Ethanol may also increase the risk of osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Folic acid absorption may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F167754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This product is contraindicated for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F167776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F167755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogen has been shown to decrease the quantity and quality of human milk; monitor the growth of the infant closely.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F167756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Estropipate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 mg (100): $43.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (100): $62.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $100.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ortho-Est 0.625 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 mg (100): $88.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ortho-Est 1.25 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (100): $109.75",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F167744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yearly physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menopausal symptoms: Assess need for therapy at 3- to 6-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of osteoporosis: Bone density measurement",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F167757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Genoral (AU);",
"     </li>",
"     <li>",
"      Harmogen (CH, GB, IE);",
"     </li>",
"     <li>",
"      Ogen (AU, BB, BM, BS, BZ, GY, ID, JM, NL, SR, TT);",
"     </li>",
"     <li>",
"      Ortho-Est (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. In males and following menopause in females, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones. Estropipate is prepared from purified crystalline estrone that has been solubilized as the sulfate and stabilized with piperazine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and in target tissues; first-pass effect",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;WHIMS Investigators. Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/26/15783/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9428 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15783=[""].join("\n");
var outline_f15_26_15783=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708759\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167767\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167788\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167771\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167772\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838038\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167773\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167746\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167730\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167747\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9958825\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167786\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167750\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167734\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167784\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167739\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167762\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167754\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167776\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167755\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167756\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167753\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167744\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167757\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167733\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167749\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9428\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9428|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/34/13862?source=related_link\">",
"      Estropipate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_26_15784="Applying stockings A";
var content_f15_26_15784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52484%7EPI%2F53659%7EPI%2F80635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52484%7EPI%2F53659%7EPI%2F80635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Putting on compression stockings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Heel-pocket-out method to put on compression stockings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 611px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJjAcgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK43x9rtxbmHR9JlCX9yN8sgPMEPTcPRmOQPoT2qZzUFzMuEHOSijsQynoQaWvONNklsIEjhlfCjua6XStdLusV1gZ4DVz08VGTs9DephZR1Wp0VFIrBlBU5Bpa6jlCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAy/Eusw6Fo819MN7L8sUQODLIfuoPqfyGT2rznSbebdNeX7+bf3TebPJ79gPQAYAHoKNVv28V+IBdgkaVZMyWidpW6NL+PQe3+8a0lGBivMxNXnlyrZHqYel7ON3uwoZgoyTSOwUZNY+paiqKQprmbsdEYtnYeH9cEUwt7h8oeFJ7V2IIYAjkGvADqbCQMGbGQBjJJJPAA7kntXtfhpbxdGtv7Rj8q4K5KE5KjsD746/1rvwdWU04vocWNoxptSXU1KKKK7TgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuG+I+tuqx6Bp0hF3eLm4dTzDB0P0ZuQPbceoFbfivxFDoVqqon2jUJgRb2wOC59WPZRnk/lk4FcTo9hMZJbzUJPPvrhvMmlIxk+gHYAYAHYCubEVeVcsd2dWGo8z55bIs2FkltaxxxqFRRgAdqc7BQatXUqomBXP6nqCxIeea82VkejFORFq2oCJSoNctcTvO38RyQqqoJLEnAAA5JJ4xTrqZp33NuOWCgAEkknAAA5JJ6AV6j4A8Gf2Xs1PV0VtRI/dRdVtgf5uR1PboO5Lo0ZVpeRdatHDx8xngDwX/Z3l6nrMatqPWGHgi2BH6vjqeg6DuT3tFFevCCguWJ4lSpKpLmluFFFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyXi7xhFpM39naai3eruP9X/BAD0aQj9FHJ9hzVPxt4untrs6N4fw2pHHnXBG5bYHtjoXI7dB1PYHL8N+Ho7NDJKDJO5LvI5yzMeSSe5rlrV7PkhuddGgrc9Tb8xmi6TK1zLqGpzPdX8+PMlfr7ADoAOwHFaly6wjAq3cusMeF4rl9XvxGGy3NcU3y+p2wTm/Ii1bURGjc81x91dSTzDhmLMFVFBZmY9AAOST6VJc3E15dJFCjzTSvsjiT7zsegH+ffpXq/gbwZHoipfalsm1VlOMcpAD1VPU+rd+2BxU0aMqz8jWtWjho+ZX8BeDf7NMep6ugOoY/dQ5DLbAjn2LkdT26DuT3dFFevCCguWJ4tSpKpLmluFFFFUQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxnjjxDPDING0SQDUpRmaUc/Zoz39N57Dt1PbPZ14VpGtxy67qVy4z9pv3O/PJUsxUfggX8BXPiajhHTqdOFpKpK76HXaBosGmW6jGXPLMxySe5J7n3rZlmWNOKpafdx3/AJt0xCWyHaijvisjVNXjUlFYelcPMorQ7eSU5WZJqV6WyAa47WpjhixOK2pJPMjLetcrrTSz3EdtbLvnmdY40/vOxwo/MiueTcmdlOKiel/CHQ4U0ka5Om68ui6RFh/qogxXA/3iMk9wQO1eiVT0exTTNJsrGLBS2hSIEDGdoAzVyvbpwUIqKPAqzdSbkwoooqyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCnrF2NP0i+vCRi3gebn/ZUn+lfMulTtZ2CBkLTxIGC92nkG1R9Qny/jX0b4zgkuvCOtQQgtLJZzKij+I7Dgfj0rwXwNCmpal9qk+aG23XJP8AediQv5KP5Vw4zoj0cDZKTOpEn9heH7a0d8zbd0h9WPJP5k1gf2dql/pMuuARxaakyRI0jkNMS4U7BjkAnqcdDitC1sJfFfiQ2zzeRYRkNdTFtuxCThQf7zYIH4ntz0fiq+i1HXrfSbBVTSdG4YJ91pgNu0eyLkfUn0rljTTg6k9uh1uo4zVOG+7Mq+K2mnpuOGI5qb4V6OdW8SS6vcJm2sOIs9GmYf8AsqnP1ZT2rnvEV3NfX6WVpF5s0jrFEin7zNwAfTk/SvbvCWiR+H9AtdPjYO8Y3SyD/lpIeWb8+noMCtMJS558z2RnjKvJT5Fu/wAjYooor1DxwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqhe6pb2rFDvkdTghAOD6Ekgfhmk2luNJvRF+vAtN0w+GvEniHQXXam4T2zf3oWzt/Lp9RXrk3iQJ92CL/AIHNg/oprh/Hl8t5JZ6pHbxiazPlytGSxMLHBBOBwG2tz0G71rlxDjOFk9TswqlTnqtGY/g69j02z8RtcxrKtlG12qnksWQjn/v2cemT61RsbhLLRVhjJebGZWAPLHk5Prk1JoEC3niW7s9rNBfWciyqT1AKj8OHYfjW1oHhS9vbpdKvRDHZRnNxKJPnuIx2UdQW/iPbJwelckYOrGKR2ynGlOTkXfhX4X8+aLxFfr+7G42UZ9Dx5h9uoUenPcY9UpscaRRpHGqoigKqqMAAdABTq9OnTVOPKjyatV1Zc0goooqzMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDh/HHxP8AD/gvxLoWh6wbk3mruFjaFVKQAuEDyksCqkk8gH7pruK+ePiF8JPFPjvxN411e7uobBZLeOz0i3KJKZ44yJB8+cxbpEBz1+Y544PuPhFtUbwxpR8QxCHWBbIt2gcMPNAAYgjjBIJ/GgC/fzfZrG4nHWONnH4DNcrptql1bbLvL7eQc87jyT+orofEJxot37pt/M4rI0sYgY/7R/Tj+lc1Z+8kdFFe62RnRyv/AB7XKj2kjB/UU2bT9ReCSFls5IZFKspzhgeCCMVrRDJp0gxUcqL5mcjoXhCXR5pJrdozNINplmlLsF/ujjp+p75rQ1C0ktYDdNc7riIhk2rgA5rZxway9ebFmV9mP5A/4ioaSWhom5PU61WDKGHQjNLTYl2xIvoAKdXecAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ/iAbtGuvZc/kQay9P/49v+BN/M1sawu7SL0Dr5L4+u01j6f/AKpsdN38wD/Wuat8SOil8Jeh60sppkZ+anSdazuXYaPumsnVB5vmL2ChB9WPP9K1R901lyjfexp/euo8/T5aT1KWh1tFFFdxxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAy4TzIJE/vKR+Yrk9LuAtuoYMdyq/AJ7Y7fSuvrlNOiP2ZDHgSR5UehGeh/Kuev0N6OzNG3dZMFSCD6VJJVWCNJSzwkxy5+Ye/uP61KJSWKSrtkHOOx9we4rHoa9Rw+6azI/m1i3A73H8l/wDrVpkhYmJIAHJNZ2nLnWbPPXLyH8Qf8aaWqB7NnVUUUV2nGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXM6Qd1ru9ST+tdHcP5UEkn91S35Cub0QbbGMf7IrnrvVG9FaMueVvYMp2SDo39D6io7gu67ZoiGHIeM5wfUd6njPNLIcmseht1KkQlnjAlXZGvJH98/0FGnDd4hX/AGYWP6gf1qyv3TVfSh/xP3P/AE7t/wChLVQ+JEy2Z0NFFFdhyBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBT1h9mk3jf9MWx9cVk6au21Ue1aPiE40e499q/mwFUbQbYAK5q3xHTR+EnSkc0qUOKxZohFHymq2kn/ioJPeBv/Qlqyv3TVTTDjxAv+1Gw/kf6VcPiRMvhZ0lFFFdhyBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVHNNHCAZGCg+vegCSiqR1GHPytmq9xqqRjg1DqRXUtU5PoatFcreeJ1t1JI4FM07xhBcOwbGFGTWf1ine1zT6tUtex1tFA6DPWitzAKKKKACiiigAooooAKKKKACikLKOpFN81M/eFFwsPopodT0YU6gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMvxGf+JcE/vyov65/pUEQxGBS+IG3T2cOf4jIR9BgfzNAGFFclV3mdVNWgPjokojpJKkoaOhqna/Jr1oc/e3r/46T/SrlUORrFkw/wCemPzBFJfEhvZnU0UUV3HEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXEfEe8ktbrRljYqJXkDY78LXb1558WDtu/Dx/6bSj/AMdFY4j+GzfDa1Yl2wJaMEmlvOFqLTX/AHI+lLethDXBf3Tut7xyfiK42IQDVDw+DJJCnXz7iKEj1DOob/x0k/hUHiKfMxGe9b3gCy+067pg6LB5l23vhdgH5yZ/CsKS5qiR1VXyUWz12iiivcPACiiigAooooAKKKKACsfxbqn9j6FPdqAX3JGg9SzAfoCT+FbFeefF+6PkaNYKeZrhpz7qi4/nIv5VnWlywbNaEOepGI621e5njVy555pZL+cDO85rOsF2WyA+lF3KFU815PPLuer7ON9ELLr11Cxw5I+taWk+L23hbgZHTNcVe3HJqot2sMbyyHCICzH2FEa84vRmksPCS1R7tY3cd5CJIjkVYrE8HWM9hoFst4Nt3KPNlU/wE87P+AjA/DNbdexBtxXNueHOyk+XYKKKKokKKKKACiiigAooooAKKKKACiiigAorO1nWbDRoVk1C4WIucRxgFnkPoqjJb8BWE3jzS3DRKt7DcOCsQltXAZuwyAQPxxUynGO7LjTlLZFqR/tWrzzDlE/dL9B1/XNWiapaXGUt0znOM5q53rjvfVnVotB6HApGPNIOKQ9aGxID0rNvH8q7tJD0WZCfpkVpnpWPrgIt2YdV5FJ9ylrodlRSKwZQw6EZpa7zhCiiigAooooAKKKKACiiigAooooAKKKKACiiigArz34sjM/h8/8ATxJ/6BXoVeffFrg6Af8Ap6cf+OH/AArHEfw5G+G/ixHaf/qFx6UmotthY+1O0z/Ur9Kg1t9sLV5u0D0VrOx51rDF7zj1r0T4VwGS/wBQuSD5cMMVuvpuOXcfl5deeSoZr7j1r134ZWn2fwws5+9ezPcZ9VztQ/8AfCLVYKN6l+xWPly0lHudZRRRXrHihRRRQAUUUUAFFFFABXkvxDmN349hgGTHa2qL9GdiW/QJXrVeNTTf2n4y1i7/AIBctEv0jxH/ADQn8a5MY7U7dzswKvUv2RsL8sI9MVjajOeea2LttkP4VyuozcmvNloenTV2Z17MS+Aa2/AemNrHiO2jK5trUi5uCRxwfkX8WGfojVzDuMs7kBFBJJ7CvbPh1oh0bw9G0y4vLwi4m45XIG1P+ArgfXJ71rhKfPO72RGNq+zp8q3Z1NFFFeweGFFFFABRRRQAUUUUAFFFFABXI6z4+0vTrw2tvBeajcBijCzRSqkdQWZlHHQ4JweDzxVT4g65OXGhaTMUupl3XUqH5oYj0APZm/MDJ4JBrGs9At/sKwBAI/L8s7eDt9M1y1sRyvljuddHDqUeaew+8+JOqSJv0rw2fJb7txd3IRfrtA5HuCRWVZeK/GOvyslteafZ2y8Pc2tuWVfZWkJ3n6AAfpW5NpcN9qaz6qEawt4x5dt/Cze46EAAYHv7CsvxHrEcUbrbgRoBgKvGBXPOvNK7Z006EG7KJVvry10qZ5Wmlu7xxh7i4ffI3tk9B7DAHpWBZeJU1LWbaBim9bgDAYZxn0ra8B+Df+EqL6rrErjTBIUjhRipnKnDEt1Cg5HHJIPIxz2XivVIba1Ph/QVhhaNQJ5EUeXaIMEKB0LkdB2HJ7AyqMpR9pN2NJVoQl7Kmrs37ZozEoUg8UrkbsCvJo7q/s4o7+1vrgkSqvlXEjOLgFgNoHRScjG0Dkj6V6nAh2gmtVK5zzp8u5LSDrS0g602Zoew4rJ1gZtnzWu3K1mamuYHqWVE6HTH8zTbRz1aJD+gqzVLQznR7L2hUfpV2u+OyOKW7CiiimIKKKKACiiigAooooAKKKKACiiigAooooAK4D4t/wCr0D/r9b/0U9d/XnvxbOX8PqOv2l2/JCP61jiP4cjfDfxYk2mgeQv0rM8QyYjYVoWBP2dfpWV4iwImzXmSfunpQXvnDszlp2hx5uCsf++eF/UivoPTLOPT9NtbKD/VW8SQp9FAA/lXh3htEl8QabGwz5l5Fgf7rb/5LXvJYDqQK6sDG0XIwzGV5qItFN8xP7wprTxqMlhXddHnWZJRUK3UR6OKd50f94UXQWZJRTVkRujA06mIKKKKAKmr3qabpV5fS/6u2heZvoqk/wBK8j8G2si2cbTcyt8zt6seSfzzXa/FS78vw9FZKfnvrhIv+AKd7fh8uP8AgVYmkRiG1HGOK8/FyvNR7Ho4SPLTcu5W1hwoIrjdQl3Pit/X7jbu5rkpZQC0kjYVQST6CuCbuz06UbK50XgjRBrniGCGVN1nbgXFz6EA/In/AAJh+SsO9e6Vy/w60aTR/Dsf2qPZe3TefMpHKZHyofooAPvmuor2MPS9nBLqeHiq3tajfQKKKK3OcKKKKACiiigAooooAKpa1qMWk6TdX84Zo7eMuVXqx7KPcnAH1q7XnvxFv2vtUstCgb92mLq7x35/dp+YLH/dX1qKk+SLkaUoe0momT4etZ5nmvr0h7y6kM0zDpuPYewGAPYCukkZYIqbYwLDbqQO1Z2pTkk815nwq73PS+N2WxWv7wnIrj9at5bonYSD7DOa255Dk1WF1DF8zcmsJO+51wXLsWPCd/4ms9GXSbaS1trRGcpO0JaZQzFjj5tvUnBIP0qPVbu30mxNvE2eSzsTksxPJY9yTySaz7/xGyRlISB9KydA0u+8T35WN2SyRz5s/oe6L6n9B+lW5yqWiiFSjTvOWh1XgC1fWr4Xs6YsbJisKn7rS9yB6KDj6n/Zr1ALhaoaHptvpenwWdpGI4Yl2qo7f/X960pRtTNdkIWRwVanPK5WdgtIpyailbJp0dJiSLP8NZ2pH9w/0rSX7lZGskrbSEelKWwR3Og0RdukWY/6ZKfzFXaZAgjgjQdFUAfgKfXelZWOJu7uFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV558UPn1jw9F7XEn5eWP8A2avQ6838bTLd+N7S3HP2O0yfYyN0/KMH8RWGJdqbOjCq9VF2zTbCo9qwPFB/dtXSxDbF+Fc74mjDQOxNebNe6ejSfvnKaDeCw1/SrjGfLmkYD38px/Wu3k8Q3Nw+dxArziI4vbD089l/8huf6V09s2DURqSjFRTN6lOMpOTWp1drfTyAZkNWxPIR8zk1i6e+a0lJ4rWM2c0oJMsrK4HDGo57yZejGnr0qrddKpt2JSVxjazPBznOKbbeNGjmCSLkE461jakxCnFcZqU8kTTspyUjdgPoCayVacXozoWHhJNtH0VZTi6s4LhM7ZY1kGfQjNTVDZQ/ZrOCAf8ALKNU/IYqLVb+DS9Nub66YiCBDI2OScdh6k9AK9n1PD3eh5/48u/7Q8WW9hHzHYw7nI/56SYOPwVVP/AqdLiC3A9qzPDkM95c3GoXo/0m5czSdwCf4R7AYA9gKm1658lGHoK8ipPmk5nsU4cqjT7HK67c+ZKVFWvh/oo1vxNCkoBtbPF1MP72D8i/iwz7hCO9c9d3G6RmY4A5JPavZ/hdo39l+GIriZMXd/i5lz1VSPkX8Fxx6k0YWn7Spd7I0xlX2VLlW7Owooor2DwgooooAKKKKACiiigAooooAoa7qtvo2mTX12WMcYACLyzsThVX3JwK810S3nmu7i+vyDd3Uhml74J6KPYDCj2Aq14n1T+3/EK29uwbTtOdgGHSWfGCfooyo9y3tUqMIE4rz8RU5pcq2R6WHpckbvdl+5uPKjxmudvrpd5yabqmqouRnmuW1HUNzEg1yTnc7KVItX2pBCcVzl9qDMxwcCoZriS5uEhhR5JZG2pHGpZnPoAOSa9M8DfDJvMi1DxQikD5o7DO4Z7GQjg/7oyPUnpSp0p1naOxrVrU8Ory37GL8PvAlx4hMeoawHg0g/MiZKvc/Tuqe/U9sDmu+8PQwxxf6PGkcWSVVBgKM8ACu2I+QqvHGBXGaIUNvH2O0civQdKNJJRPJdeVduUjei60ly3y4pIQ3Z8/UUy5Dd2GPYUdCepRY/NViA5NVHBz941Na53ffP6VmWaOPlrI1oj7LID3BrTI45Y4rK1Mr5LgenNOQR3OshbfEjDuoNOqppDF9Ks2bqYUz+Qq3XctUcT0YUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACMQqlmIAHJJ7V4/oMrapq99qknJu52kU/7HRB+CBRXc/EjUGsfCdzHExE96RZxkdfn4Yj3CBj+Fc/4dsBaWkS4A4zj2rixUrtQXqd2EXLGU36GwIxjb6CuZ8UHFswrp7Q75H9MVzfiyPEbD2zXLUXu3Omi/fseejJaFx/yzuUb8zt/9mrprc/NXMXEbfYr0RnDrGzqf9peR+orpLNg4VlOQRkVzLY7p7m7YHBFbCcgVjWIywraRcKK3hsclTclzgVUnPBqy3Sqkx4qpGcTC1NsKa5WBBdatBAeRNPHD/326r/Wug1uXaGrH8JJ9o8W6XH/AHruNv8Avg7/AP2SsYK9RLzOt+7Sk/I+g68q8WatN4m1xbCyY/2TZyYYr0uJQcE+6qeB6nJ7Ka6/x9rMmlaOIbN9uoXrGCAjqnGWk/4CP1KjvWD4b0uOws4+MEAAfSvSxM2/3a+Z5WGgl+8fyLNvAtlZ9MHFcV4jmMjPg122ty4tzivO9WkyzV59bTRHo4dNvmZz6W5u7uG1xkXEqQn/AIEwX+tfTwGBgdK+ePDMPmeItLyP+XyA/lIp/pX0PXZgF7rZyZk/fivIKKKK7zzQooooAKKKKACiiigAriPiF4glhKaLpc2y8nXdcSofmgiPHB7M3OD2AJ64re8Wa2mhaS9wFWS6kPl20JP+skI4B9hgk+wNeZ6bZyr5lxdSNNdzMZJZW6ux6n2+nYYFcuJrci5Y7s68LR53zy2Rd0y2hs7ZIolCIgwAKZqN0EjIzzUVxN5eecAVy+rakSxGa8yUrKx6sIczuVtVugrMxaum8F+AbnX7aPUNXlktNPk+aKJBiWZf72T91T24JI9OM5Pw+0L/AISfxMguV3WFnie4BHD8/Ih+pBJ9lI719AjgcV14XDqa55nNjcU6b9nDfqY2geGdH0AH+yrCKGQjDTHLSMPdzkke2cVs0UV6KSWiPJbbd2FY02hojl7GTyiTkxsNyfh3H8vatmilKKluEZOOxhrDeQZDwFh6xsGH9D+lV7l5m4ENxn/ri/8AhXSUVm6K7miqvscj9kvpf9XbS4/2sL/MirFvp2oq2WiQD3kFdNRQqERuvIyEsrtlwwjX3LE/0p8OjQ7g10xnOc7SML+Xf8Sa1KKpUooh1JMKKKK0ICiiigAooooAKKKKACiiigAooooAKKKKACiiigDzn4jTi78UaNpufkgja5df9pjtQ/ksn51at7lWluIkwDGnArmvFt9Ha/Ea8ubg4jgWOMsegHlhv/ZzTJdTXTtZW4Y/6PcgJu7DJ4/pXlVan7xnr0qX7qK8rnReGr0zXdzE/VKqeMQVUn2rnb6+l0jxJZzRtiC5cRyD68D9cV0HjWVfsCOD95c1nzXptPoaclqqa6nntvKryyRZyx4YexrU8OMW0qwZjyYIyf8AvkVzenbjb6jPGMylpQg9SCVH8hXVaVHstoEClQiBNp7YGMfpWKVkdMndnR2HUVtLyorDtGCgZNakNwm3G4VtBnLUWpaYZFUrnhTU32hf7wqpdSqQcEVUnoRFO5y+uc7qg+G8XmeOdMP/ADzeR/8AyDIP/ZhVnV1yGNUfC+orouoXWogBpobSXyEP8crNGiD82GfbNZ0f4qbOmtf2Mkjr9WnGseNLqbfvtrH/AESIdgRgyH67uD/uCteafkKnAHFcnYFdG0aESsXmYbmZurMeST7k81Po2sNezhJYpI2aMSxlkKh0JIDDPUEg8j0q3UcpN9zBUuWKXY1dZk/0fHeuE1T7xruLz95HIZOABmuHux5kRlPTdgVlU1OihoTeEufE2jqO92n6ZP8ASvfa8O8GQg+L9DUdRcOx/CGQ/wBBXuNejgV+7+Z5uYO9VegUUUV2HAFFFFABRRRQAUUUUAeeeKYpLvxCZrnPlwr5cCdlHUn6k4/ACqkwCRV3er6Yl4m4DEg6GuI1q2mtQVdDj1rzK9OUZOTPUw9SMoqKOW1S4xurjb+TdIxAJPoBkn2A9a6TVwxLbRWh8MPDcmp+IkvbpCLSxIlORw8n8C/h94/RfWuSEHUmoo9CVRUabm+h6X8PPDv/AAjfhyG3lA+2zHz7lh/fI+7n0UAL+Ge9dNRRXuxioqyPnZScm5PdhRRRTJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPK/idpXkeIbe/YZtb+PyHP9yZQSv8A30uf++PeuQsUW90O+0q4GZbQEIe5iOdv5cj/AIDXuevaTb63pU9hdgiOQAh1+8jA5Vh7ggGvB9XFz4X15G1dPIYEwyuRiOeM/wAaHoecHHUcivNxVJqXMtmerhKylDke6Ga1dPfeEba+Y/6RbZEh/wBuM8n81zXX+KSX0GBxzlK4vYsaappsjr5N2plgbPVsYYD8MH866ZLsX/guzk3DeYhkehxyPzrk6M62rSRW8C+FBfWi3T3vlgzu+wR56SscZz7V6FF4d06OaaRkkkaWV5SC2ACzEkDHbmuU8Cz/AGewjXdwWcn2JYn+tdvb3BkB2oT9eK6oKPLscdWU+bcI9Oso/u2sX4jP86nEMK/dhiH0QUDzCOQo/HNGH7uPwFaWRjdvdjtq/wB1fyFRy20Eo/eQRN9VFOKP2kP5Ck/egfwN+lMRm3nh7TLpSHgKE943I/8ArVzV94At1ure4tr8qISzbJkzknA6jHv2712M7sqltrKffkVl6heN5WWPFZuMexrGpNbM5fUtCudRuEge6QKSEPlqc4J5x6HGcH1rS3R33jG+lgVUsrJFsIQOm2PO78mZl/4DWes97cXvm2t79khXgMqqWY+uSDj8Ofeq891baDok0UNwXYBmaRjkjuST3+vWsuaMYtI3UJyknIqeK/EDG9+w2QGXJ3Nn7qjqa55NSilVWY4tY2wrdfMb29ayNPin1e6Yqksj3LbSkYy8h5xEv05LHoOeeuPYPCPwyt4DHeeJBHc3AA8uyQ/uIB6H++fXPHtxSp0ZVmaVK8KESp8LNIuLvVTrs8bR2aIy25YY81mwCw/2QMjPfdx0r1WkUBVAUAAcADtS16lKmqceVHj1qrqy5mFFFFaGQUUUUAFFFFABRRRQAVFPbxTLiVAw9xUtFDVwTsY1x4b0y4bMlupP0rRsLKCwtlgtY1jjHOB3PrViipUIp3SLc5SVmwoooqiAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorntV8beFtJ1QabqniLSLO/OB9nnu40cZ6ZBPGe2etAHQ02REkQpIqup6hhkGnUUAc9J4J8NSSmSTRLBiTuwYhtz/u9P0rkfE3w3lWdrjwvJDDCeWsJCVTPcowzjPoRjPcV6fRWc6UJqzRrTrTpvmizxnQtN1TS7qRdS0+e0RiNpfBUnnOGUkdvWvQNPUCIGrni6Pfo5b/nnIrfrj+tVNOINuv0rldNU3yo6vauquZ7lupYIt/J6VDVtTtjAFVFa6mcn2HeVHioLqErGWj7dqkzzSu/y1bs0QrooBw8dYlxpg1i8exEzwAxsxkjAJX04PHWtK2f/W88BjSeFg0usX8x6IoQfic/0rKK5pJM1k3FNow4fh5eF8XGsxCIf88bQhj+LOQPyNW5/hf4fu0VdQN/d7Tn95clQT7qmF/Su6orpjQpx2RhLEVZbyMbQPDGkaAGOlWaxOw2mRnaR8em5iSB7DitmiitEktEZNtu7CiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvmPwJq3g3wtZ+J9F+J+mCTxVcanPJNHc6c1zLfox+QxNtO5T25AHXjOa+nKKACiiigAooooAy/E/wDyA7n/AID/AOhCsrSjm2WtXxOcaHc++0f+PCsvSx/o4+lctb4jppfAXl61OW6VXxS9qhOxbVyfIqO4cKhPoKZk4qG6yYyM8mm2JIoRnZbyOe5JrT8JQ7dPknI+aaQtn2HA/rWNqsnlWvlryxGAK63Trf7LYwQd40Cn645qqKvK4qztGxYooorqOUKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAxfFjhdMVO8kqr/AF/pVSwG2ID2qLxjP/plhAO25yPyA/rVizH7sZ64rkqO8zrpq0EWKKeiZFDrtqbDuMzTHAxk9qdUVy22In2pDMiEG9161ixlVfcfoOf6V29cp4UQSandSkZ2IF/M/wD1q6uuigvduYV371gooorYxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikLqOpFAC0VGZox1cfnTRdQE4Eq5+tK6HZk1FAORkUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHE643n+KHHaJVT9M/1rXgGFFYTkyeIL1/+mzL+XH9K34egrh3k2du0Ui0nSlcZFOQcUOOKuxFyq3WqGpvsgY+1X361lawf3DVm2aR3J/A2WjvXPd1H5A/411Fc54HQrpk7f3pj/IV0dddL4EctX42FFFFaGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXzfafHnXpLtf9H8NXBOsHTBpUU0qXzpu2+YMkqB7njrX0hQBx3ivxDPp2txWEQUK8Cyhu+SzA/wAhVJtRupl+aU/hWb8UAY/FmkSD/lpbOv8A3y6//FVNa5aJTjtXmV5y9o1c9WhCPsoysVtSuZxG371/zrl7nUbiAZSZ92eOa3tbfZG1cZeSZOWOAOa45tndSirHtHw4u57zwnb3N5IXleWYZJ7LIyj/ANBrpvMT+8K8j8AalM/hqyiRyFEYJHueT+pNdL9omx9816UcSlFK2x5U8M3Ju+52huIx1cfnTDewAZMi4+tcLNNJg5c/nWLf3Ugzh2/OlLGW6Djg+bqeqpeW7/dlX86nBBAIOR614rbahOkvMrY+teleB71r3RnMjl3ineMn8iP0IrShifau1jPEYX2Kvc6Ciiiuo5AooooAZNNHCoaVwoJwM9zTFuoW6SKfxrzvXdUk1XxbcRwyA2Wng24A6NKcFz+HC+xU+tSbyvIYiuOeK5ZNJHZDCc0U29z0UMG6EGlrz+21ySzkG6QlfQmuu0rVoL+MbXG/0rWliI1NOplVw8qevQ0qKKK3MAooooAKKKKACiiigAooooAKKKKAOCsfnv7hz/FK5/U10MPasHTOZXb1Yn9a3oa4Ed0i7H0FEnSkTpRJ0rXoZdSpLWNrD/uyK15jWFq54rGRtE3/AAeu3RUP952P64/pW3WX4YXbodqPUMfzY1qV209Io46msmFFFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4W3wGvJtGv9CuvFkLaBf6g1/PDHpCLcZLhtqzGRtv3Rzt9eOSK9yiQRxoi52qAoycnAp1FAHm3xYXGs+H5PSO5X8zCf6GjTjut1NWfism6fQm/wCmsq/moP8ASobBAtsuPSvMxC/es9Sg/wByjD8RHANcHrchSyumH3hG2Prjiu68TcAmuA1ph9kcH+J1X/x4Vxv4jvh8Fztvh6NulRj2rse1ct4MTZYxj2rqe1bROae5VuvumsHUK37r7vNYGpEYNRMukYkkmJcV6Z8KznQ74/8AT6//AKAleWzAmbivUvhSuPDlw3968kP5BR/StsD/ABH6GeYfwl6nZ0UUV6x4wVieMtaGgeHrm9UBrjiO3Q/xStwo+nc+wNbdeY+Nrv8AtvxZDpsfzWumDfIR0M7Dp/wFSP8Avs+lZVqns4Nm1Cn7SaT2M/wxYta6cgcl5W+d2bqzHkk+5PNaF1J5aHNWlAhjxjGKwNXuvvAGvIloj14+8zM1C4YuTnip9B1prS6U5ZuQAq8liTgADuSeKxriXe2M12fwv8PLeXh1m5ANtbMUtl/vyDhn+i/dHvn0FKhCVSaSLxE406bcj1G33+SnmjD7RuHoakoor3T58KKKKACiiigAooooAKKKKACiiigDhdK6475rfj7Vg6fxdSgdnYfrW9F2rgR3MuR9KSbpSp0ps33TWvQy6mdcN1rC1Rs5rauT1rntVbrWEjeJ3OiJs0eyH/TJT+YzV2obJdlnAuMYjUY/Cpq9BaI4HqwooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOD+KfP8AYa/xfaXP4eWf8RVaxBFuKd8TJd2vaFbjtHPK3scxgfzapLZcQj6V5uI1qs9OhpRRzXij/VmvO9WO6W0jHJMu4j2AP9SK9G8UjEZrzudHfWtPIHyAOp+pGR/6Ca4/tnfF/uz0fwyNltGvtXRDpXN6C2No9q6QdK0hsYVNype/dNc5ftwa6O++4a5i+zk1My6Rkuf3tesfC1ceEIn/AL9zcH8pnX+leTf8thXsPw4TZ4M0/wD2zLJ/31Izf1rowC99mGYv3EvM6WiiivUPIMvxPqy6HoV5fsod4k/doTjfIeFX8SRXnXhCxkhtjPcuZLiZjLLIeruxyx/EkmrPji/bX/E0OlWxzZac+6Yjo85HT/gIJ/Fj/dq6xFpbY6YFediKnNO3RHpYenyQv1f5FPWbsJkA81xmp3XB55NX9YvdzsSa5qeR55AER5HJCqiDLMxOAAPUkgVwTlzM9KlBRV2aPhrSLjxFrMdhblkQ/PPMP+WUQPJH+0eg9znoDX0DZWsFjaQ2tpGsVvCgSNF6KoGAK57wD4ZXw5pG2ba2o3JEly69AeyA/wB1Rx7nJ7109exhqPsoa7s8XF4j209NlsFFFFdByhRRRQAUUUUAFFFFABRRRQAUUUUAcJb/ACatdp/dncf+PGugh7VhSjZ4gvV/6ak/nz/Wt2HoK4dmzueyLi9KZN9009elRzH5TV9DPqZV42FNc9dZnuEiHV2Cj8Tit6/PymsrSYvP160X0k3f98gn+lZ2u7Gq0Vz0AcUUUV3nAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlnjKX7V8QCg5W2toovoxLsf0ZK2YgBEBXMwS/2h4s1i8HIe7dQfZMRj9EFdOq/JXlSfNUkz1kuWnGPkYHiaEPasR1FefwqP7QiJ/g/efrs/8Aagr0vVkLQOteY6pIbK6STHyGVI5D6KXU5/NVrB6SOmGsLHb6Gf3grplPFcpoLZkBByK6pegop7E1dyte/cNc3eDOa6W8+4a5u/bAOKJjpGQI8zivavBsQh8JaMgGP9DiJ+pQE/rXiN1N5UM0ufuIzfkM171o0TQaRYwuMNHBGhHuFArqwC1kzmzJ6RRcrlfG3iU6TEtjpxWTWLkfu1IyIV6GRh6eg7n2BIi8XeLGsZ20zRFS41Uj5y3KWwI4Lerei59zgYzz2h6M8UklzeSvcXkzb5ZpTlnPv/gOAOBXTWr8vux3OSjQv789vzJtB0pbC03sS0jZZ3bqzHkk+5JJrN1++2ggGtjV7zyISqntXn+q3TTOSTxXm1JW0R6lGDk+ZlDULgu5ANdx8JvDf2y4Gu3qZt4GK2ino7jIaT6DkD3yewNcd4c0W48Ra5DYQFkRvnnlH/LKIHk/U9B7nPQGvoe1t4rS1it7ZBHBEgREXoqgYArfBULv2kvkY4/Ecq9lH5ktFFFeoeOFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcXqg2eJ7n/a2n/wAdFbEB4FZXiMeX4jQ/34lP6kf0rTt/uiuGXxM7V8KLqnio5z8pp6dKiuPumqJMXUG4NN8JRb9Zdz0jjJ/EkD/Gmak3BrQ8Fx8XcvqVUfhk/wBRU01eaKnpBnTUUUV3HEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMnlWCCSWQ4SNSzH2AzT6yfF7tH4T1p0+8tlOw+ojahgjy/wAHfNDFIwAaQb2+p5P867OIA1zPhqEJDGF7Cumg+41ePS1PYrblPUod0bY9K8y8R2YkMsT5CuCpI7e9eqzYkiPtxXn3iiPbKRUVV1Rrhn0ZR8DXjunlTH97EdjfUV6JG2UFeWaG/keIGA4EyK31IJB/TbXp9scwg0osdREd23yGubvmyTW/en5DXNXhzuxSmx0kZNyguEktxyZ8Qj/gZ2/1r2fxvrz6NpyRWeDqd4TFbKRkKccuR6KP1IHevJNDtzP4g0mM87r6Fv8Avlw5/RTXaW0o8QeI7zWHybaM/Z7PPTy1PL/8CbJz6bfSunDS5KTa3bOfFxU6qT2SJPDeiJaQh5SzyuS8kjnLOxOSxPck81r3rpAhIpwk5Cr0FYmv3gAK56UNqESEnOepga1fb2YVzFx87cVcvpjIzVTtrea+uoLO2OLi5kWGM/3Sxxu/AZY+wri1m7I9JWhG76Hqnwi0tbXw7JqDJia/kLZPXy1JVPwPzMP9+u6qCxtYbGyt7S2XZBBGsUa+iqMAfkKnr34RUIqK6HzlSbnJyfUKKKKogKKKKACiiigAooooAKKKKACiiigAooooA5Txam3VLGT+8jL+RH+NXLX7gpnjBPlspf7shX8xn+lFmcxiuOppNnXB3gi+h4qG4PFSR9KiuOhpdB9TndWbANdB4NXbo+7+/Ix/kP6Vzur9K6zw5F5WiWi+qbvzOf61VBXmKs/cNKiiius5AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqtqVqL7Trq0Y4WeJ4ifZgR/WrNFAHj/AIPuWKRwSYEnlAH2YcEfnXQWN0DcXMDn58AqKwPGenTaN4muTZv5K3ga8tm25AfP7xcd/mIb/gftWbe627aXa65bjZJE+25iHOMH51/nj8DXjtOnJx7HtK1WKkuv5nV6bdZuri2lYBicqDXJ+O/9FdmfgAbjVrXZjBr2jXkTZjeZVJB4YP8AKP1YVB8V1AsppP8Apix/SoesbMuHuzTXVHFWs5N9p0x4Lq3A99pr1bTpN1qp9q8bvpPIOmspxhyv6f8A1q9L0LVYWskDyDdj1pLRIqpq2aV83ytXO3I+8a0b7UYOfnH51zWqaiX2W9oA9xO4jjBPc/071LTk7IqHurUdZQXGravFa2LMkduS9xIp5KsrIUX3IY89vUZBrur3U7TRtPCjbGqLwvTaBXP6G8Hh3TJoJGEkqtveY/8ALRiOSPT0+lY+kxz+L9T87BGmxvwT0lIP/oIP5n266bLlRm1zNylsehaNfi709Ljay7xnDDBxWHr04aRhmttxBZwbS6oqjqTXK3ky3UssicRjp70pvSwUkuZtGRKMmuv+FGmfaddutQePMVknlIx6ea4yce4TH4SVyFy/lxs4VmI6KoyWPYD3PSvbfBujf2F4etbOTBuMGSdh3kY5b8BnA9gK1wVPmnzPoRj6vLT5F1NqiiivWPFCiiigAooooAKKKKACiiigAooooAKKKKACiiigDG8Vx79J3j/lnIrfrj+tUtObdEtbGuoZNHuwOojLD8Of6Vz+jvuiFctbSR00neJrocGorg8GpF61FcfdNZM0RzesHg4613ttH5NtFEOiIF/IVw1wolv7eP8Avyqv5sBXe1th1uzOu9kFFFFdJzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBznjzSX1TQ2e1jMl9Zt9ot1HViAQyf8CUkfUg9q8ctXiNxLFEw+zajGXRT2lUfzKgg/7tfQ1cj4l8A6TrlwbpWnsL0tvM1qwG5h0ZlIIJ9TwSOM1y4jD+096O52YbEql7stjyaedz4OtHbPmadLt+gjbcv/joU1tfE0faNMZUxkwsP0NLqPgbxNZvexLb2+o2Nwvz+RKEYt03BHxgkdRk9BisW5jmCC31RZYr+IBZYJPvZx1+hHINefOM6a95Ho05QqSXKzf0H4d2s9lFea+wuYyA8UMbEAZHUkfWurj8H6AYAq6ZGox/C7A/nmo/BV4174VsojkyQDyJCf7yfLn8cZ/GunjXC4rqjFW0OKc5OV29Tkn8D6Ir+YlnK5Bzta5fH86w9fm0GzuBpk+nz2VwFE0U1tGWYYPVWGTweoI7+9ekMK5LxnpKanAhDeVcwtvhlA5Rv6g9CO9DVloEZNvVnm11ZPd38VtEL+ZJXJE12iooHchQBk+7cDrg12N3qFp4Y0VYLdRvVQoCjJJ6AD1rLZvEEVi9x/ZFzcJCSpktQJAT6gZ3d/T865kXwOoG5vt1zfqMx2yg4jz7np/vHHtXLLmXSx2xUZdbl+aWcgahrsz7nP7q2Q5wewwPvH/PvUqXpJRLsLC7/MkC/MwX1bH/AOr61kPf4nZ5J4X1FwcySHEduvoo7/T8T2Fd78PvBP8AaG3UNVRzYEh1SYfPdt/efP8AB6Dv/u8FQpOo7IqpVjSjdk3gHw9Pqup2+q3MTRaZAwliLDBuHH3SB/cB5z3IGMjNes0AAAADAHQCivXpUlSjyo8WtVlVlzSCiiitDIKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEkUOjI3KsCD9K4rRMoWib7yHafqOK7auP2eRr17H0Bk3j/gQz/Wueutmb0HujYFQ3P3DUq1Fc8qawZsjDtxu1uzH/AE1U/rmu6rh7T/kPWY/6af0NdxW+H2ZjiN0FFFFdBgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVg+KvDFj4hgBnVo7yJSIbiI7XX2PYr7EEVvUUmlJWY4ycXdHEeELCHT9KWGAMBuLMWOWLE5JNdFGPlrNt08jVL6AfdEm8f8C5/rWnH0rjStodcnfUjkFYuqrlTW5LWXqKbozSkOJe8GjGjn3lb/AAq3q+h6ZrIj/tSxt7ox/caRASvrg9RVfwnxpAHpI/8AOtmuuCvBHLNtTbRVh0+zhtobeG0t0gh/1caxgKn0HarVFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcvqJU+IpSnUIqt9cf4EV1FcfGpbVrx26+c4/U4/SsK70SN6C1bNdT8tRTHK1Iv3aZIODXKdBjWoxr9n/wBdP6Gu2rjI1267ZH/poK7OurD7M56+6CiiitzAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5/Uh5WvqR0lhH5gn+mKuJ0qDXRjUrBvUSD/0Gpk6VyTVpM6o6xQklZ982yIsa0JKpXieZbuvtWci4k/hWZXt7iIfeSTdj2I/xBrcri9AufsuqxhjhJh5R+vb9ePxrtK6qMrxOetG0gooorUyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuZnUR61eKOhKt+aj+tdNXLSP5muXzdgwUfgAKwxHwo3obs0E6U2UcU+PpSP0rnRuYty4i1G0kPAWZM/TIrs64jXU/d5HBrsbKb7RZwTf89I1f8AMZreg90Y11syaiiiug5wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDF17BvrAd/nP/AKDUsfSqdxKLrWZGXmOFfLB988/4fhV+NeK5JPmk7HVHSKuRyVXl+430qxLxVaYgKc1DRaObuQyx71O1g2VPoa7+3k823ikPBdQ35iuE1ImRxFEu52ICqO5Nd3bRmK3ijPVFC/kK0w/UzxHQkooorqOYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARiFUknAHJrjdLYzPJOw5lcufxOa6TXZfJ0m5YHDMuwfVuP61h6XFsjUVzV3dpHTQVk2aiDC01ulThflqGQYBrK1i73MHW3xGc1otqctg2mWNvLYtILdRJDPIUYEBcfMM4zyOh5xWffp591BCekkiofoSBWzf6owuri3t7NLgh1tiVdS4dl3Dcpx8mD1z68VVPqxVOiNKwu1u43PlvFLG/lyRvjKNgHHHB4IOR2Iq1WP4Vt0ttKwjSs7SN5hlxu3qdjDjjAK4HoMDpWxXVFtq7OWSs7IKKKKoQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUtXu/sdi7qR5rfJH/ALx/zn8Ku1zF9N/aOp8cwQkqnue5/p/+us6kuVGlOPMyTSYPLhXOcnnmtVeBUMKbVGBUrHArCKsjaTuQTnrWVfThFNaNw3ymsR4je6hBaqTh2+YjsOp/Solroi46as0fDOn+Y39oTjnkRA9uxb+ldJTY0WONURQqKAAB2FOrshFRVkck5OTuFFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc54pnL3VnZqe5lf+Q/r+VS2qbQBWXC5vdZurlum8onso4H+P41tQjmuOT5pNnWlyxSLA+7UE3SrJ+7VaeiWwo7mNJ8uq2TH7vnJ/Op5pbe7Rr+70d2j3tturR90qbSVycbXBwOi5qrrKHyQ6nDKcgjsa29Mt47q1S8glmt5LhQ0oib5S3QnacgHPcAGnT10CrpZlzR1gXTLY2gcQMgdTJksd3OTnnJzk/WrlRwRJBBHDEMRxqEUZzgAYFSV1LRWOZ7hRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFR3MyW9vJNIfkjUsfoKAM3XL/wAlDa25P2iQckfwKe/19Kp2EHlRqMc1mWN09xHJfSLGTIPNYtLjav5cDFXo7uVbeOd7Zgr7cKHBbLEADn61xylzu51xjyqxrrwKZIaqterG6pKkqMwJAKbunX7ufWkF3DKcRyxsfQNz+VNsSQ26bCGqnhkeZrM7nnZEQPxI/wAKkv3xExNSeDoG8u6uWHEjBF9wuefzP6VNPWaKnpBnR0UUV2nGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNlbbG7DsCadTJgWhcDqVIoA4/QF/wBFVj1IrdhHNec2HjG3tLW1za3jiYqsezy8knpxnIrag8b6el2ttcRX0MzKW2vBu4Hf5fqK4Izj3PQlSn2OybpVWY1mW/ivRbiRol1K2WZQCUkPlsM+oP0q2biOUbo2V165RgwqpNPYzUWtzP1o/wCjGtnwhn+wYAezPj/vo1zuszBkwD0611uiW5tdJtYWGGCAsPQnk/qaqh8TZNb4Ui9RRRXWcoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYfiafckNlGcvMwZx6KD/AFOPyNXNY1KPToM43zuD5cfdj/hWFYq5drq6LNNJyTtP+QKxqz+yjalD7TM66057e7tYIplFtJuOyTgEgqQmfQ8nH+zg5FXYLsXN+oucKtqfugEhn6bjjoAP1J/u1ptsmTa6b1PUMhI/lVB7Ge3jlSxa18tizoksfMZPJxg9M9qxRtcsQSG51GeYH91CPIT3bOXP6KPqpqG18m6uLmZ9reY3loGwcqmRwP8AeLfpWcieRpxS0ju/tgiKhDHzvKkcvjB5561NBLZR2KxLeWqRgbdrLiQH0xnO72x+FJ6gtBdbItY40gyXkJ+QngKByfbt07kV19nAtraxQJ92NQv1965K4heeG7uZkZDIoSNWHIQdyOxJJP0x6V1WmzfaNPt5c5LRgn645/WtKNk2Z1r2RZooorpOcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPCfFfhs+E/Emlm3uhLaP50tuksePKIIGM7sMQGI/h696g0HUorrXNTvrwHdtW3XAyoPU8+5I/Kvdb6xtNQg8m/tYLqHOdk0Ydc/QivLvEfw61RE1IeH30820xlniidSjxsxLbFwCMZPB4xx6ZrhrYd3vE9GhiotctT7zH8NW8NxZ6lqdwikXMh2bh/AvAP06n8ag8F6VaSafLdszQzzyvIhjkKNtzhcYPoAapXOl6ouk3Fnp2k6t9p8kowa1kXAx0DEBeB0/T3itr2wttOg23Fr+7C7disrZB9z1rk5eXfQ7U+bRM7Pw1Jcah4r/smeQ3EMaee0j4yFUqCCe+dwFer15/8LdEurdr7WdRikhluwqQxSDDCMcliOoySOD2UetegV6OGi4w97dnlYqSlUtHZBRRRXQcwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcRq5vLPV57q/tJJbct8k0Z3AJ2GO2PfHOalh1izkAbzWC+hQ/0GK7Kq0thaTMTLa27k92jB/pWLpa3TNlVVrNGTaajYSYxcoP8Aeyv86lvWQrkEMvUEVak0XTnHFnEnvGNh/wDHcVQn8OKob+z7ua3J/hbDofwP881LpysNTjcpQM/nYVuPfmtOKMk7js3eoXmswaRrcT5jksHHq24H+VW4rbXF++NPI9i1QoyXQ0covqOvI2aJ1DcEdxTfCM58u4tHOTE29fo2cj8wT+NPaPUsES2Mb+8Uw/k2P51DotlfQav5z2zQwFWV97KSe4xtJ5yP51UU1JOxMmnFq50lFFFdJzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVF02wS7N0llbLck5MwiUPn/exmrdFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The heel-pocket-out method to put on compression stockings is as follows:",
"    <br>",
"     <ol>",
"      <li>",
"       Turn the leg part of the stocking inside-out down to the heel (as shown in A).",
"      </li>",
"      <li>",
"       Put your foot into the stocking, hold onto the folded edge, and pull the stocking onto your foot and over the heel (as shown in B).",
"      </li>",
"      <li>",
"       Gently work the stocking up your leg by turning it right-side out (as shown in C).",
"      </li>",
"     </ol>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Using a stocking donner to put on compression stockings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15784=[""].join("\n");
var outline_f15_26_15784=null;
var title_f15_26_15785="Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1";
var content_f15_26_15785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/26/15785/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15785/contributors\">",
"     Andrew W Tai, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15785/contributors\">",
"     Raymond T Chung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/26/15785/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15785/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/26/15785/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15785/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/26/15785/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H148839828\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the introduction of the",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protease inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    , only 40 to 50 percent of patients with chronic hepatitis C virus genotype 1 would achieve a sustained virologic response (SVR). With the addition of these protease inhibitors, the rate has increased to 70 to 80 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link&amp;anchor=H8#H8\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    . The approach to the treatment of patients with HCV genotype 1 is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838069\">",
"    <span class=\"h1\">",
"     TELAPREVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    has been the most thoroughly studied",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protease inhibitor in humans. A phase I dose-ranging study of telaprevir monotherapy found that while the majority of subjects had marked declines in HCV RNA over the 14-day dosing period (median change of -4.41 log",
"    <sub>",
"     10",
"    </sub>",
"    in the 750 mg every eight hours arm), several patients had viral breakthrough during the dosing period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/1\">",
"     1",
"    </a>",
"    ]. The rapid emergence of viral resistance mutants to telaprevir monotherapy likely reflects the large number of viral quasispecies in the infected host that results from the highly error-prone HCV RdRp. However, these resistant variants remain sensitive to the broad antiviral actions of interferon. As a result, subsequent clinical trials combined telaprevir with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H148838165\">",
"     'Viral resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838076\">",
"    <span class=\"h2\">",
"     PROVE trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phase IIb Protease Inhibition for Viral Evaluation (PROVE) trials 1 and 2 evaluated combination therapy with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in treatment-na&iuml;ve patients with chronic genotype 1 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], whereas a third trial (PROVE 3) looked at the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    in patients who had failed previous antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148840016\">",
"    <span class=\"h3\">",
"     PROVE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;In PROVE 1, a total of 263 patients were randomly assigned to one of three",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    groups or to a control group. The control group (PR48) received peginterferon alfa-2a (180 mcg each week) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (1000 or 1200 mg daily according to body weight) for 48 weeks plus placebo for the first 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/4\">",
"     4",
"    </a>",
"    ]. The three telaprevir groups all received the same dose of telaprevir (1250 mg on day 1 and 750 mg every eight hours thereafter) for 12 weeks along with either 12 (T12PR12), 24 (T12PR24), or 48 (T12PR48) weeks of peginterferon plus ribavirin.",
"    <br/>",
"    <br/>",
"    The SVR rate was significantly higher in the T12PR24 and T12PR48 telaprevir groups compared with the control group (61 and 67 versus 41 percent, respectively). However, the rate of discontinuation because of adverse events (mainly rash) was significantly higher in all three telaprevir-based groups (21 versus 11 percent in the control group).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148840023\">",
"    <span class=\"h3\">",
"     PROVE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;In PROVE 2, a total of 334 patients received one of the following regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       Telaprevir",
"      </a>",
"      (1250 mg on day one then 750 mg every eight hours) and peginterferon alfa-2a (180 mcg each week) for 12 weeks",
"      <span class=\"nowrap\">",
"       (T12/P12)",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       Telaprevir",
"      </a>",
"      plus peginterferon plus weight-based",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 12 weeks",
"      <span class=\"nowrap\">",
"       (T12/PR12)",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       Telaprevir",
"      </a>",
"      plus peginterferon plus weight-based",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 12 weeks followed by",
"      <span class=\"nowrap\">",
"       peginterferon/ribavirin",
"      </span>",
"      for an additional 12 weeks",
"      <span class=\"nowrap\">",
"       (T12/PR24)",
"      </span>",
"     </li>",
"     <li>",
"      Standard of care",
"      <span class=\"nowrap\">",
"       peginterferon/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      for 48 weeks (PR48)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An SVR was achieved in 69 and 60 percent of patients in the",
"    <span class=\"nowrap\">",
"     T12/PR24",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     T12/PR12",
"    </span>",
"    arms, respectively, while the SVR was 46 percent in the standard of care PR48 arm and only 36 percent in the",
"    <span class=\"nowrap\">",
"     T12/P12",
"    </span>",
"    arm. The difference was statistically significant for the comparison between the T12PR24 versus control arms (ie, 69 versus 46 percent). Adverse events occurred significantly more frequently in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    -treated patients. In particular, 12 percent of patients across all telaprevir treatment arms discontinued therapy due to skin rash.",
"   </p>",
"   <p>",
"    These data suggest that in treatment-na&iuml;ve patients, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    may significantly increase SVR rates compared with peginterferon plus ribavirin alone, with the possible additional benefit of a shorter course of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148840030\">",
"    <span class=\"h3\">",
"     PROVE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;In PROVE 3,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    was given to 453 genotype 1 chronic HCV patients who had been null responders or relapsers to prior therapy with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/6\">",
"     6",
"    </a>",
"    ]. Forty-three percent of subjects had cirrhosis or bridging fibrosis. The treatment regimens studied were (1)",
"    <span class=\"nowrap\">",
"     T12/PR24;",
"    </span>",
"    (2)",
"    <span class=\"nowrap\">",
"     T24/PR48;",
"    </span>",
"    (3)",
"    <span class=\"nowrap\">",
"     T24/P24,",
"    </span>",
"    no ribavirin; and (4) standard of care PR48.",
"    <br/>",
"    <br/>",
"    The overall SVR rates were 51, 53, 24, and 14 percent in the",
"    <span class=\"nowrap\">",
"     T12/PR24,",
"    </span>",
"    <span class=\"nowrap\">",
"     T24/PR48,",
"    </span>",
"    <span class=\"nowrap\">",
"     T24/P24,",
"    </span>",
"    and PR48 arms, respectively. Comparing these four arms by subgroup, the SVR rates were 69, 76, 42, and 20 percent in prior relapsers; 57, 62, 36, and 40 percent in prior breakthroughs; and 39, 38, 11, and 9 percent in prior null responders. Treatment was discontinued due to adverse events in 15 percent of patients who received telaprevir with peginterferon and ribavirin, compared with 4 percent of patients who received peginterferon and ribavirin alone. While up to 60 percent of individuals in the telaprevir-treated arms experienced a rash, the rate of treatment discontinuation due to rash was relatively low (4 to 6 percent in the PROVE 3 trial). Nonetheless, it appears that a rash is frequently experienced among patients taking telaprevir.",
"   </p>",
"   <p>",
"    Of note, the PROVE trials enrolled few African-Americans or Latinos, populations that experience significantly lower rates of SVR with standard",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     .",
"    </span>",
"    Nearly 75 percent of the PROVE 1 trial participants were white, while 94 and 90 percent of the PROVE 2 and 3 participants were white, respectively. Subgroup analyses of the PROVE 1 and 3 trial data suggest improved SVR rates among African-Americans treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    compared with standard of care (SVR rates of 40 to 44 percent versus 10 to 11 percent). PROVE 1 also showed a benefit in Latinos who received telaprevir compared with those who received standard of care (SVR rates of 65 versus 33 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66470121\">",
"    <span class=\"h3\">",
"     Open-label follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in the control arms of the PROVE trials (ie, those treated with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    only) who were either null responders or relapsers had the option of being retreated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , peginterferon, and ribavirin in an open-label study. The study included 117 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/7\">",
"     7",
"    </a>",
"    ]. All patients received 12 weeks of telaprevir, peginterferon, and ribavirin followed by either 12 or 36 weeks of peginterferon and ribavirin. The initial protocol called for a total of 24 weeks of therapy",
"    <span class=\"nowrap\">",
"     (T12/PR24).",
"    </span>",
"    However, it was later amended so that prior null responders and patients with detectable HCV RNA at weeks 4 or 12 received a total of 48 weeks of therapy",
"    <span class=\"nowrap\">",
"     (T12/PR48).",
"    </span>",
"    Prior relapsers who had undetectable HCV RNA at weeks 4 and 12 continued to be treated for a total of 24 weeks",
"    <span class=\"nowrap\">",
"     (T12/PR24).",
"    </span>",
"    The overall SVR rate was 59 percent. SVR rates varied by the patients' prior treatment response:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior null responders to treatment &ndash; 37 percent (17 percent for",
"      <span class=\"nowrap\">",
"       T12/PR24",
"      </span>",
"      and 56 percent for",
"      <span class=\"nowrap\">",
"       T12/PR48)",
"      </span>",
"     </li>",
"     <li>",
"      Prior partial responders to treatment &ndash; 55 percent",
"     </li>",
"     <li>",
"      Prior viral breakthrough while on treatment &ndash; 75 percent",
"     </li>",
"     <li>",
"      Prior relapsers following treatment &ndash; 98 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838083\">",
"    <span class=\"h2\">",
"     ADVANCE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pivotal phase III trial studied",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    and was called A New Direction in HCV Care: A Study of Treatment-Naive Hepatitis C Patients with Telaprevir (ADVANCE) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/8\">",
"     8",
"    </a>",
"    ]. In this trial, 1088 treatment-na&iuml;ve patients with genotype 1 chronic HCV were randomly assigned to one of three arms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       Telaprevir",
"      </a>",
"      750 mg Q8h in combination with peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 8 weeks, followed by additional weeks of peginterferon and ribavirin as described below",
"      <span class=\"nowrap\">",
"       (T8/PR)",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       Telaprevir",
"      </a>",
"      750 mg Q8h in combination with peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 12 weeks, followed by additional weeks of peginterferon and ribavirin as described below",
"      <span class=\"nowrap\">",
"       (T12/PR)",
"      </span>",
"     </li>",
"     <li>",
"      Peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 48 weeks (PR48)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    arms who achieved an extended rapid virologic response (eRVR; HCV RNA &lt;25 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    at both weeks 4 and 12) stopped therapy at week 24, while those who did not achieve an eRVR but did become undetectable by week 24 continued peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for a total of 48 weeks. Erythropoiesis-stimulating agents were not allowed for the management of anemia. An eRVR was achieved by 57 and 58 percent of the patients in the",
"    <span class=\"nowrap\">",
"     T8/PR",
"    </span>",
"    and the",
"    <span class=\"nowrap\">",
"     T12/PR",
"    </span>",
"    arms, respectively, whereas only 8 percent of patients receiving PR did so.",
"   </p>",
"   <p>",
"    SVR rates were significantly higher in patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    for 8 or 12 weeks compared with patients who received standard of care (69 and 75 percent, respectively, versus 44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/8\">",
"     8",
"    </a>",
"    ]. In a subgroup analysis, 62 and 74 percent of African-American and Latino patients, respectively, in the T12PR arm achieved an SVR compared with 25 and 39 percent, respectively, in the PR48 arm; however, the number of non-white patients in the trial was small.",
"   </p>",
"   <p>",
"    Rashes occurred in 35 and 37 percent of the patients in the",
"    <span class=\"nowrap\">",
"     T8/PR",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     T12/PR",
"    </span>",
"    arms, respectively, compared with 24 percent of patients in the PR48 arm. However, only 5 and 7 percent of patients in the",
"    <span class=\"nowrap\">",
"     T8/PR",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     T12/PR",
"    </span>",
"    arms, respectively, discontinued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    due to rash events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838090\">",
"    <span class=\"h2\">",
"     REALIZE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to ADVANCE, a second pivotal phase III trial called REALIZE (Re-treatment of Patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    -based Regimen to Optimize Outcomes) studied 663 patients with genotype 1 HCV who had previously failed",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy with SVR as the primary endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/9\">",
"     9",
"    </a>",
"    ]. Treatment failures included relapsers (354 patients), partial responders (&ge;2 log",
"    <sub>",
"     10",
"    </sub>",
"    decline in HCV RNA at week 12, but failure to achieve undetectability by week 24; 124 patients), and null responders (&lt;2 log",
"    <sub>",
"     10",
"    </sub>",
"    decline in HCV RNA at week 12; 184 patients). The treatment arms were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       Telaprevir",
"      </a>",
"      , peginterferon, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 12 weeks, followed by an additional 36 weeks of peginterferon and ribavirin (T12PR48)",
"     </li>",
"     <li>",
"      Peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      alone for 4 weeks, then",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      , peginterferon, and ribavirin for an additional 12 weeks, followed by another 32 weeks of peginterferon and ribavirin (lead-in T12PR48)",
"     </li>",
"     <li>",
"      Peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 48 weeks (PR48)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SVR rates were significantly higher in the two",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    arms compared with placebo. Overall, SVR rates were 64 percent for the T12PR48 arm, 66 percent for the lead-in T12PR48 arm, and 17 percent for the PR48 arm. Subgroup analyses based on prior response to treatment also showed higher SVR rates for patients treated with telaprevir: previous relapsers (83 percent for T12PR48, 88 percent for lead-in T12PR48, and 24 percent for PR48), partial responders (59, 54, and 15 percent, respectively), and null responders (29, 33, and 5 percent, respectively). Among the 143 patients with cirrhosis, SVR rates were significantly higher in those who received one of the telaprevir-based regimens compared with those who received peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    alone (49 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/10\">",
"     10",
"    </a>",
"    ]. As expected, SVR rates among patients with cirrhosis treated with telaprevir-based regimens varied by prior response: 84 percent, 34 percent, and 14 percent in prior relapsers, prior partial responders, and prior null responders, respectively. Treatment was discontinued in 4 to 5 percent of patients in the telaprevir groups due to rash and in 2 to 3 percent due to anemia, whereas no patients in the PR48 group discontinued treatment due to rashes or anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838100\">",
"    <span class=\"h2\">",
"     ILLUMINATE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;ILLUMINATE was a phase III noninferiority trial of 540 treatment-na&iuml;ve patients with HCV genotype 1 designed to evaluate differences in SVR rates between a 24-week and a 48-week",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    -based treatment regimen in patients who had an extended rapid virologic response (eRVR; HCV RNA &lt;25 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    at both weeks 4 and 12). Patients were treated with telaprevir, peginterferon, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients with an eRVR who remained on treatment were assigned at week 20 to continue peginterferon and ribavirin for a total of 24 or 48 weeks.",
"   </p>",
"   <p>",
"    An eRVR was achieved in 352 patients (65 percent), 322 of whom were assigned to either 24 or 48 weeks of treatment. Patients who did not achieve an eRVR were treated for 48 weeks. The overall SVR rate was 72 percent, with 7 percent of patients stopping treatment due to virologic failure and 18 percent stopping due to adverse events (most often fatigue or anemia). An intention-to-treat analysis showed an SVR rate of 60 percent among African-Americans and 67 percent among Latinos compared with 74 percent among Caucasians. Among patients with an eRVR, the SVR rate in the 24-week treatment arm (92 percent) was noninferior to the SVR rate in the 48-week treatment arm (88 percent). Among those with an eRVR, race and ethnicity were not predictors of an SVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838116\">",
"    <span class=\"h2\">",
"     EXTEND study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    -based therapy appears to be durable. In the EXTEND study, patients from some of the prior telaprevir trials, including the PROVE trials, who achieved an SVR are being followed long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/12\">",
"     12",
"    </a>",
"    ]. In an interim analysis with a median of 22 months follow-up, 122 of 123 patients (99 percent) maintained an SVR. One patient experienced a relapse 47 weeks after early discontinuation from PROVE 2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154623739\">",
"    <span class=\"h2\">",
"     Telaprevir for genotypes 2 and 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    has also been studied in small numbers of patients with genotypes 2 and 3, with mixed results.",
"   </p>",
"   <p>",
"    In a randomized trial, patients with genotype 2 (23 patients) or genotype 3 (26 patients) were assigned to one of three treatment arms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group 1:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       Telaprevir",
"      </a>",
"      for two weeks followed by peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 24 weeks",
"     </li>",
"     <li>",
"      Group 2:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       Telaprevir",
"      </a>",
"      plus peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 2 weeks followed by peginterferon and ribavirin for 22 weeks",
"     </li>",
"     <li>",
"      Group 3: Placebo plus peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 2 weeks followed by peginterferon and ribavirin for 22 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After three days of therapy, the decrease in HCV RNA in patients with genotype 2 who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    appeared to be greater than for patients who did not receive telaprevir (no p-value given), though virologic breakthrough rapidly developed in six of nine patients receiving telaprevir monotherapy. The decrease was greatest in patients who received telaprevir, peginterferon, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    as their initial therapy. There was limited activity of telaprevir in patients with genotype 3 infection: group 1 patients only had a -0.54 log",
"    <sub>",
"     10",
"    </sub>",
"    median decrease in HCV RNA at day 15 of telaprevir monotherapy versus baseline, and the addition of telaprevir to peginterferon and ribavirin did not significantly reduce median HCV RNA compared with",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    alone at day 15 (-4.85 versus -4.72 log",
"    <sub>",
"     10",
"    </sub>",
"    ).",
"   </p>",
"   <p>",
"    Among patients with genotype 2, an SVR was attained in 5 of 9 group 1 patients (56 percent), 5 of 5 group 2 patients (100 percent), and 8 of 9 group 3 patients (89 percent). Among patients with genotype 3, the SVR rates for groups 1, 2, and 3 were 50 percent (4 of 8), 67 percent (6 of 9), and 44 percent (4 of 9), respectively. The authors do not report whether any of the observed differences in SVR rates were statistically significant. The finding that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    appears to reduce HCV RNA in patients with genotype 2 but not genotype 3 infection is consistent with",
"    <em>",
"     in vitro",
"    </em>",
"    data indicating that cell culture infectious HCV expressing genotype 3 NS3-4A is much less sensitive to telaprevir than HCV expressing genotype 2 NS3-4A [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/14\">",
"     14",
"    </a>",
"    ]. Given the very small numbers of patients in this study, the conclusions can be viewed only as hypothesis-generating. A larger study of the efficacy of telaprevir in patients with genotype 2 infection would be of considerable interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838123\">",
"    <span class=\"h2\">",
"     Effect of IL28B genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient's IL28B genotype is a known determinant of the patient's response to treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    and appears to affect the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    -based regimens as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H16092947#H16092947\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'IL28B polymorphisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study of triple therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , peginterferon, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in 81 Japanese patients examined the effect of genetic variation near the IL28B gene on treatment response rates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/15\">",
"     15",
"    </a>",
"    ]. Thirty-three patients were relapsers, and 21 were null responders to prior treatment. Twenty patients received 12 weeks of triple therapy (T12PR12), while 61 received 12 weeks of triple therapy followed by an additional 12 weeks of peginterferon and ribavirin (T12PR24). The sustained virologic response rate following triple therapy was significantly higher in patients with the TT genotype compared with patients who had non-TT genotypes (84 versus 28 percent; odds ratio 10.6). As in the PROVE 3 trial, prior null responders to peginterferon and ribavirin experienced substantially lower rates of SVR (23 percent) compared with prior relapsers (86 percent) and treatment-na&iuml;ve patients (76 percent), most likely because prior null responders were more likely to carry unfavorable IL28B genotypes. The interpretation of the study results is limited by generalizability to non-Japanese populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838130\">",
"    <span class=\"h2\">",
"     Telaprevir dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be possible to give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    every 12 hours instead of every 8 hours. In a randomized trial with 161 treatment-na&iuml;ve patients with genotype 1, every 8 hour dosing was compared with every 12 hour dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients were assigned to receive standard doses of peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    along with 750 mg of telaprevir every 8 hours or 1125 mg every 12 hours for 12 weeks. Patients then continued to receive peginterferon and ribavirin for an additional 12 or 36 weeks based upon their virologic response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=see_link&amp;anchor=H15546553#H15546553\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\", section on 'Shortening therapy for patients who achieve an RVR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SVR rates were similar between those patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    every 8 hours and those who received it every 12 hours (83 versus 82 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838137\">",
"    <span class=\"h1\">",
"     BOCEPREVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     Boceprevir",
"    </a>",
"    is another protease inhibitor for the treatment of chronic HCV infection. Boceprevir is a competitive inhibitor of the NS3 protease complex of HCV genotype 1. As such, it does not have significant activity against other HCV genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838144\">",
"    <span class=\"h2\">",
"     HCV SPRINT trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase II study (HCV SPRINT-1) that included 595 treatment-na&iuml;ve patients with genotype 1 HCV compared the following treatment regimens: (1) peginterferon",
"    <span class=\"nowrap\">",
"     alfa-2b/weight-based",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (800 to 1400 mg daily) for 4 weeks followed by the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    for either 24 or 44 more weeks (lead-in); (2)",
"    <span class=\"nowrap\">",
"     boceprevir/peginterferon/low-dose",
"    </span>",
"    ribavirin (400 to 1000 mg daily) for 28 or 48 weeks (no lead-in); or (3) standard of care",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/19\">",
"     19",
"    </a>",
"    ]. In a second part of this study, \"low-dose\" ribavirin (100 to 400 mg daily) was compared with \"full-dose\" ribavirin (800 to 1400 mg daily) in combination with boceprevir and peginterferon for 48 weeks.",
"   </p>",
"   <p>",
"    The 48-week",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    lead-in group achieved an SVR rate of 75 percent versus 38 percent for the standard of care group. The 28-week boceprevir lead-in group had an SVR of 56 percent. The 48- and 24-week no lead-in groups had SVR rates of 67 and 54 percent, respectively. In part 2 of SPRINT-1, the \"low-dose\"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    group had an SVR of only 36 percent compared with 50 percent for the \"full-dose\" ribavirin group.",
"   </p>",
"   <p>",
"    Anemia was more common in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    -treated patients; for patients who were not given erythropoietin, treatment discontinuations due to adverse events were between 10 and 26 percent for patients in the boceprevir arms compared with 9 percent in the control arm. The use of erythropoietin reduced the discontinuation rate due to adverse events to 2 to 8 percent in the boceprevir arms. No increase in rash or pruritus was observed in the boceprevir arms compared with the control arm.",
"   </p>",
"   <p>",
"    HCV SPRINT-2 was a phase III trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    in treatment-na&iuml;ve patients with genotype 1 HCV. It included 938 non-black patients and 159 black patients who were enrolled and analyzed separately. All received peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    during a four-week lead-in period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/20\">",
"     20",
"    </a>",
"    ]. After the lead-in, patients were assigned to one of three groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group 1: peginterferon,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      , and placebo for an additional 44 weeks",
"     </li>",
"     <li>",
"      Group 2:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      , peginterferon, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for an additional 24 weeks, followed by 20 more weeks of peginterferon and ribavirin if HCV RNA was detectable between weeks 8 and 24",
"     </li>",
"     <li>",
"      Group 3:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      , peginterferon, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for an additional 44 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapy was discontinued in patients who were HCV RNA positive at 24 weeks. For non-black patients, the SVR rates were 40, 67, and 68 percent, for groups 1, 2, and 3, respectively. The increases in SVR rates for the two regimens containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    were statistically significant when compared with group 1. For black patients, the SVR rates were 23, 42, and 53 percent, respectively. The difference in SVR rates between groups 1 and 3 was statistically significant, but the difference between groups 2 and 3 was not. Forty-four percent of patients in group 2 had persistently undetectable HCV RNA between weeks 8 and 24 and were treated for a total of 28 weeks; the SVR rates in this group were 97 and 87 percent for nonblack and black patients, respectively.",
"   </p>",
"   <p>",
"    Patients with the favorable IL28B CC genotype were more likely to attain an SVR than those with the CT or TT genotypes (odds ratios [OR] 2.6 and 2.1, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/21\">",
"     21",
"    </a>",
"    ]. Other factors associated with an SVR in previously untreated patients included a low baseline HCV RNA level (OR 11.6), the absence of cirrhosis (OR 4.3), genotype 1b rather than 1a or other (OR 2.0), and non-black race. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H16092947#H16092947\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'IL28B polymorphisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838151\">",
"    <span class=\"h2\">",
"     RESPOND trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;RESPOND-2 was a phase III trial with 403 patients who were prior partial responders or relapsers with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/22\">",
"     22",
"    </a>",
"    ]. Null responders (&lt;2 log",
"    <sub>",
"     10",
"    </sub>",
"    decline in HCV RNA at week 12 of prior therapy) were not studied in this trial. As in HCV SPRINT-2,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or placebo was started after a four-week lead-in of peginterferon and ribavirin. Patients were then assigned to one of three groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group 1: peginterferon,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      , and placebo for an additional 44 weeks",
"     </li>",
"     <li>",
"      Group 2:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      , peginterferon, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for an additional 32 weeks, followed by 12 more weeks of peginterferon and ribavirin if HCV RNA was detectable at week 8 but undetectable at week 12",
"     </li>",
"     <li>",
"      Group 3:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      , peginterferon, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for an additional 44 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapy was discontinued in patients who were HCV RNA positive at week 12. This occurred in 61 percent of the patients in group 1, 22 percent of the patients in group 2, and 18 percent of the patients in group 3. As expected, SVR rates were higher for prior relapsers than for prior partial responders. Prior partial responders achieved SVR rates of 7, 40, and 52 percent in groups 1, 2, and 3, respectively, whereas prior relapsers had SVR rates of 29, 69, and 75 percent, respectively.",
"   </p>",
"   <p>",
"    An interesting finding in this study was that the virologic response to the four-week lead-in of peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    was a predictor of response not only in group 1 (standard of care) but also in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    treatment arms. That is, patients who had a &lt;1 log",
"    <sub>",
"     10",
"    </sub>",
"    decline in HCV RNA at week four of peginterferon and ribavirin had SVR rates of 0, 33, and 34 percent in groups 1, 2, and 3, respectively, whereas patients who had a &ge;1 log",
"    <sub>",
"     10",
"    </sub>",
"    decline had SVR rates of 25, 73, and 79 percent, respectively. Unlike the response seen in treatment-na&iuml;ve patients, IL28B genotype was not a predictor of an SVR in previously treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H148838144\">",
"     'HCV SPRINT trials'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While RESPOND-2 did not enroll prior null responders to prior peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    therapy, the SVR rates among poor interferon responders in this trial were similar to those observed in prior null responders in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    PROVE-3 and REALIZE trials. This underscores the prognostic significance of interferon responsiveness for treatment success even with the addition of first-generation protease inhibitors to peginterferon and ribavirin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H32984769#H32984769\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Changes in viral load during treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anemia was more common in patients in groups 2 and 3 compared with group 1 (43, 46, and 20 percent, respectively). Erythropoietin was used by 41 and 46 percent of patients in groups 2 and 3, respectively, compared with 21 percent of group 1 patients. However, therapy discontinuation due to anemia was rare (0, 0, and 3 percent of group 1, 2, and 3 patients, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838165\">",
"    <span class=\"h1\">",
"     VIRAL RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two features of hepatis C virus (HCV) that increase its ability to develop viral resistance mutations to protease inhibitors. The first is the error-prone nature of the RNA-dependent RNA polymerase (RdRp). It has been estimated that the RdRp introduces approximately one error per 10",
"    <sup>",
"     4",
"    </sup>",
"    RNA bases copied, while the HCV genome is itself only 10",
"    <sup>",
"     4",
"    </sup>",
"    bases in length.",
"   </p>",
"   <p>",
"    The second is that the average infected individual generates on the order of 10",
"    <sup>",
"     11",
"    </sup>",
"    new HCV genomes daily. Thus, it can be estimated that nearly 10",
"    <sup>",
"     10",
"    </sup>",
"    of these genomes will have one mutation, while over 10",
"    <sup>",
"     8",
"    </sup>",
"    HCV genomes per day will have two mutations.",
"   </p>",
"   <p>",
"    With these estimates in mind, it should not be surprising that virologic breakthrough was seen in some patients within only two weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/1\">",
"     1",
"    </a>",
"    ]. A follow-up study to the telaprevir monotherapy study showed that the great majority of HCV sequences recovered from patients experiencing virologic breakthrough after a 14-day course of telaprevir monotherapy encoded telaprevir resistance mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/23\">",
"     23",
"    </a>",
"    ]. Although the proportion of resistant sequences was markedly reduced at follow-up three to seven months later, 9 of the 12 patients who had virologic breakthrough still had detectable resistant viral genomes three to seven months after their last exposure to telaprevir.",
"   </p>",
"   <p>",
"    However, preliminary results from a follow-up study suggest that retreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    may be possible in patients who developed telaprevir-resistant HCV variants after receiving telaprevir monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/24\">",
"     24",
"    </a>",
"    ]. The study included nine patients who were previously exposed to a 14-day course of telaprevir. Clonal sequence analysis was available for eight of the patients following the original 14-day study, and all had telaprevir-resistant HCV variants. A median of 5.7 years after their last telaprevir exposure, the patients were treated with telaprevir, peginterferon, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 12 weeks, followed by 36 weeks of peginterferon and ribavirin. None of the patients had resistant variants detected at the start of the study. An interim analysis performed after eight weeks of therapy found that only one patient had an unconfirmed viral breakthrough. The remainder had HCV RNA levels &lt;25 int.",
"    <span class=\"nowrap\">",
"     unit/mL.",
"    </span>",
"   </p>",
"   <p>",
"    The presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    resistance mutations has also been examined in patients from the EXTEND study who failed treatment with telaprevir, peginterferon, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/25\">",
"     25",
"    </a>",
"    ]. After a median follow-up of 29 months, 83 percent of 162 patients who failed to achieve an SVR and who had sequence data available did not have detectable resistance variants.",
"   </p>",
"   <p>",
"    Resistance mutations have also been seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    . An analysis of boceprevir resistance mutations from the SPRINT-1 phase 2a trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/19\">",
"     19",
"    </a>",
"    ] was performed in 15 patients who did not attain an SVR [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15785/abstract/26\">",
"     26",
"    </a>",
"    ] on triple therapy; six had an incomplete virologic response, eight had an on-treatment virologic breakthrough, and one had a relapse. Approximately 2200 clones were sequenced for each time point, giving a lower limit of detection of resistance mutations of 2.5 percent. Not surprisingly, amino acid variants associated with boceprevir resistance were identified in all patients with treatment failure. While resistance mutations were no longer found in some patients after follow-up, in others resistance mutations were detectable as late as 90 weeks after discontinuation of treatment. This suggests that, at least in some individuals, resistance mutations to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and boceprevir do not appear to impair viral fitness significantly and could potentially persist over long periods of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838172\">",
"    <span class=\"h2\">",
"     Effect on treatment decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influence that the development of these mutations should have on treatment decisions is unresolved. The theoretical concern is that the development of mutations to one protease inhibitor could adversely affect future treatment with protease inhibitor-containing combinations (either new combinations using the same protease inhibitor or combinations using related protease inhibitors). Whether this will prove to be the case, however, is still unknown. One group of patients for whom this may be particularly important is prior null responders to",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     .",
"    </span>",
"    While studies have shown that other groups, including relapsers to prior therapy, respond well to protease-containing regimens, patients who were prior null responders do not appear to do as well. As noted above, in the PROVE 3 and REALIZE trials, the SVR rate for combination",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"      telaprevir",
"     </a>",
"     /peginterferon/ribavirin",
"    </span>",
"    therapy in genotype 1 prior null responders was as low as 14 percent in patients with cirrhosis. On the other hand, prior relapsers to peginterferon and ribavirin had excellent SVR rates in these two trials and are thus likely to achieve an SVR with protease inhibitor-containing regimens. (See",
"    <a class=\"local\" href=\"#H148838076\">",
"     'PROVE trials'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The question then is, given the theoretical concern over viral resistance, should null responders receive protease inhibitor-containing combination therapy? The argument against treating is that the anticipated 60 percent of patients who do not achieve an SVR may have poorer response rates to future attempts at therapy if viral resistance mutations persist and decrease the effectiveness of other protease containing regimens. However, the argument in favor of treating is that failing to treat would deny an SVR to the approximately 30 to 40 percent of patients who would respond, and it is not yet known whether the viral resistance mutations will actually persist long enough to influence future attempts at treatment.",
"   </p>",
"   <p>",
"    We suggest that protease inhibitor containing regimens be considered in treatment-na&iuml;ve patients with HCV genotype 1 as well as in patients who relapsed or experienced viral breakthrough during prior attempts at treatment. In addition, we believe that treatment is likely warranted in prior null responders with advanced fibrosis. However, for null responders without significant fibrosis, our preference is to discuss with the patients the lower likelihood of response to protease inhibitor-containing combination therapy and the theoretical risk of viral resistance influencing future attempts at treatment should the patient fail to respond. On the other hand, there are others who believe that it is incorrect to withhold therapy based upon a theoretical concern, given a proven real benefit for some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148840037\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the studies above, rash is a common side effect in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , and anemia is common with both telaprevir and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    . The approach to patients who develop side effects from telaprevir or boceprevir is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link&amp;anchor=H148836436#H148836436\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Side effects of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148838954\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       NS3/4A",
"      </span>",
"      protease inhibitors are the first direct acting antiviral agents to be approved for clinical use in combination with peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for the treatment of chronic hepatitis C virus (HCV) genotype 1. These treatment regimens have been shown to increase SVR rates in treatment-na&iuml;ve patients and in those patients who have previously failed",
"      <span class=\"nowrap\">",
"       peginterferon/ribavirin",
"      </span>",
"      therapy. Relapsers appear to do much better than null responders when re-treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      plus peginterferon and ribavirin:",
"      <br/>",
"      <br/>",
"      Response rates to protease inhibitor containing regimens vary depending upon the patient's prior treatment:",
"      <br/>",
"      <br/>",
"       Treatment-na&iuml;ve patients: response rates between 67 and 75 percent",
"      <br/>",
"       Prior relapsers: response rates between 69 and 88 percent",
"      <br/>",
"       Prior partial responders: response rates between 40 and 59 percent",
"      <br/>",
"       Prior null responders: response rates between 23 and 38 percent",
"      <br/>",
"      <br/>",
"      However, response rates to protease containing regimens among African Americans are lower (approximately 40 to 50 percent), but are higher than those seen with peginterferon and ribavirin alone (approximately 10 to 30 percent). Prior null responders with cirrhosis have had SVR rates as low as 14 percent with telaprevir-based therapy. (See",
"      <a class=\"local\" href=\"#H148838069\">",
"       'Telaprevir'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H148838137\">",
"       'Boceprevir'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link&amp;anchor=H148839646#H148839646\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Efficacy of protease inhibitor containing regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Due to the rapid development of viral resistance in patients treated with protease inhibitor monotherapy, patients with HCV genotype 1 should receive combination therapy with a protease inhibitor, pegylated interferon, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . Since ribavirin appears to significantly reduce relapse rates even in protease inhibitor-based regimens, it continues to be an important component of protease inhibitor-based regimens. Patients with severe chronic kidney disease or a prior known intolerance to ribavirin are therefore much less likely to benefit from protease inhibitor therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While protease inhibitors substantially increase SVR rates in genotype 1 chronic HCV, patients should be made aware that approximately 20 to 30 percent of treatment-na&iuml;ve individuals with genotype 1 infection will not achieve an SVR with combination protease",
"      <span class=\"nowrap\">",
"       inhibitor/peginterferon/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"       .",
"      </span>",
"      This is even more significant for null responders to prior",
"      <span class=\"nowrap\">",
"       peginterferon/ribavirin",
"      </span>",
"      treatment, of whom only 14 to 33 percent will likely attain an SVR even with the addition of a protease inhibitor. Interferon responsiveness will remain a strong predictor of treatment success in first generation protease inhibitor-containing regimens. (See",
"      <a class=\"local\" href=\"#H148838165\">",
"       'Viral resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that protease inhibitor-containing regimens be considered in treatment-na&iuml;ve patients with HCV genotype 1 as well as in patients who relapsed or experienced viral breakthrough during prior attempts at treatment. In addition, we believe that treatment is likely warranted in prior null responders with advanced fibrosis. However, for prior null responders without significant fibrosis, our preference is to discuss with the patients the lower likelihood of response to protease inhibitor-containing combination therapy and the theoretical risk of viral resistance influencing future attempts at treatment should the patient fail to respond. On the other hand, there are others who believe that it is incorrect to withhold therapy based upon a theoretical concern given a proven real benefit for some patients. (See",
"      <a class=\"local\" href=\"#H148838172\">",
"       'Effect on treatment decisions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/1\">",
"      Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/2\">",
"      Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/3\">",
"      Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/4\">",
"      McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/5\">",
"      H&eacute;zode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/6\">",
"      McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/7\">",
"      Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology 2011; 54:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/8\">",
"      Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/9\">",
"      Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/10\">",
"      Pol S, Roberts SK, Andreone P, et al. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: Subanalysis of the realize phase III study. Hepatology 2011; 54:374A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/11\">",
"      Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/12\">",
"      Zeuzem S, Sulkowski MS, Zoulim F, et, al. Long-term follow-up of patients with chronic hepatitis C treated with tepalprevir in combination with peginterferon alfa-2a and ribavirin: Interim analysis of the EXTEND study. Hepatology 2010; 52:436A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/13\">",
"      Foster GR, H&eacute;zode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/14\">",
"      Gottwein JM, Scheel TK, Jensen TB, et al. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011; 141:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/15\">",
"      Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/16\">",
"      Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/17\">",
"      Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/18\">",
"      Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/19\">",
"      Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/20\">",
"      Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/21\">",
"      Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/22\">",
"      Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/23\">",
"      Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/24\">",
"      Sarrazin C, Reesink HW, Zeuzem S, et al. Retreatment with telaprevir/PEG-IFN/RBV after a short exposure to telaprevir in phase I studies: Interim results from a phase IIIb rollover trial (C219). Hepatology 2011; 54:377A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15785/abstract/25\">",
"      Sherman KE, Sulkowski MS, Zoulim F, et al. Follow-up of SVR durability and viral resistance in pateints with chronic hepatitis C treated with telaprevir-based regimens: Interim analyis of the EXTEND study. Hepatology 2011; 54:485A.",
"     </a>",
"    </li>",
"    <li>",
"     Howe JA, Qiu P, Ogert RA, et al. Frequencies of Resistance-Associated Amino Acid Variants Detected by 454 Sequencing During Combination Treatment With Boceprevir Plus Pegintron (Peginterferon Alfa-2b)/Ribavirin in HCV (GT1)-Infected Subjects. EASL 46th Annual Meeting.  March 30th - April 3rd, 2011. Berlin, Germany.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16593 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-AB557005D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15785=[""].join("\n");
var outline_f15_26_15785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H148838954\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148839828\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148838069\">",
"      TELAPREVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148838076\">",
"      PROVE trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148840016\">",
"      - PROVE 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148840023\">",
"      - PROVE 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148840030\">",
"      - PROVE 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66470121\">",
"      - Open-label follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148838083\">",
"      ADVANCE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148838090\">",
"      REALIZE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148838100\">",
"      ILLUMINATE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148838116\">",
"      EXTEND study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154623739\">",
"      Telaprevir for genotypes 2 and 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148838123\">",
"      Effect of IL28B genotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148838130\">",
"      Telaprevir dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148838137\">",
"      BOCEPREVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148838144\">",
"      HCV SPRINT trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148838151\">",
"      RESPOND trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148838165\">",
"      VIRAL RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148838172\">",
"      Effect on treatment decisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148840037\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148838954\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=related_link\">",
"      Response-guided therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_26_15786="Parathyroid hormone therapy for osteoporosis";
var content_f15_26_15786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parathyroid hormone therapy for osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/26/15786/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15786/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/26/15786/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15786/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/26/15786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/26/15786/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/26/15786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid hormone (PTH) is an 84-amino acid polypeptide secreted by the parathyroid glands in response to relatively small changes in serum calcium (",
"    <a class=\"graphic graphic_figure graphicRef54710 \" href=\"UTD.htm?23/48/24335\">",
"     figure 1",
"    </a>",
"    ). Like all peptide hormones it has an N-terminal and C-terminal region. The first two amino acids in the N-terminal region of the molecule are obligatory for activation of the PTH 1 receptor (PTH1r), a membrane surface receptor expressed in multiple tissues including cartilage, bone, breast and kidney. While circulating, the intact 1-84 PTH peptide can be cleaved to several fragments at various tissues, although it is unclear if these fragments have intrinsic biologic activity. On the other hand, recombinant PTH 1-31 and 1-34 retain all of the biologic activity of the intact peptide (1-84) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parathyroid hormone (PTH) is one of the two major hormones modulating calcium and phosphate homeostasis, the other being calcitriol (1,25-dihydroxyvitamin D). With respect to calcium, PTH is most responsible for maintaining serum ionized calcium concentrations within a narrow range, through its actions to stimulate renal tubular calcium reabsorption and bone resorption. Chronic exposure to high serum PTH concentrations (as seen with primary or secondary hyperparathyroidism) results in bone resorption. Given this observation, exogenous parathyroid hormone (PTH) would seem to be an unlikely candidate for the treatment of osteoporosis. However, intermittent administration of recombinant human PTH (both full-length 1-84 or fragment 1-34) has been shown to stimulate bone formation more than resorption, at least over the first 12 months of treatment.",
"   </p>",
"   <p>",
"    This topic review will discuss the use of recombinant PTH as a therapy for osteoporosis. PTH physiology and other treatments for osteoporosis are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=see_link\">",
"     \"Parathyroid hormone secretion and action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anabolic therapy for bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH 1-34 (teriparatide, Forteo) and PTH 1-84 (PreOs) belong to a new class of anti-osteoporosis drugs, the so-called \"anabolic\" agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/2\">",
"     2",
"    </a>",
"    ]. These drugs, in contrast to antiresorptive agents, stimulate bone formation, activate bone remodeling and are administered subcutaneously as daily injections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/3\">",
"     3",
"    </a>",
"    ]. Other agents in this class include growth hormone (GH), IGF-I and PTH-related peptide (PTHrp). PTH 1-34, teriparatide, at a dose of 20",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    is available in the United States and Europe for the treatment of severe osteoporosis in both men and women, while PTH 1-84 is approved in Europe but not in the United States. A PTH 1-31 preparation has been studied in a small phase two trial.",
"   </p>",
"   <p>",
"    None of the other anabolic hormones are approved for the treatment of osteoporosis, although GH has been approved for the treatment of adults with GH deficiency and low bone mineral density (BMD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bone remodeling unit",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH stimulates preosteoblasts to mature into bone-forming osteoblasts that lay down collagen and subsequently mineralize matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/4\">",
"     4",
"    </a>",
"    ]. Bone formation begins within the first month of PTH treatment and peaks six to nine months after initiation of daily PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/1\">",
"     1",
"    </a>",
"    ]. Since the remodeling unit is always coupled (ie, bone formation equals bone resorption), once preosteoblasts are stimulated, they release cytokines that can activate osteoclasts resulting in bone resorption.",
"   </p>",
"   <p>",
"    Markers of bone turnover indicate that bone resorption in patients on PTH begins at about six months and peaks after 12 months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. It is thought that increased bone formation in the first three months precedes bone resorption and places the remodeling unit in a positive balance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. But, long-term PTH treatment leads to a re-equilibration of the bone remodeling unit, such that resorption catches up to formation, resulting in coupling of the remodeling sequence, and a subsequent plateau in the acquisition of new bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anabolics versus antiresorptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bisphosphonates, estrogens and calcitonins are antiresorptive agents which slow bone turnover, decrease bone resorption and enhance BMD, as more mineral is gradually deposited in older remodeling units [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, PTH enhances bone turnover by initiating greater bone formation. Most of the gains in BMD occur in the first few months, although antifracture efficacy is evident only after six months or more of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients on bisphosphonates will often have incremental improvement in BMD even after 10 years of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/11\">",
"     11",
"    </a>",
"    ], while it appears that the BMD changes with PTH begin to level off after 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10,12\">",
"     10,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hence, there are fundamental differences in the mode of action of PTH and the skeletal response compared to the antiresorptive drugs such as the bisphosphonates, estrogen and calcitonin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Molecular and cellular level",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of PTH action have not been fully delineated, nor has the paradox been resolved as to why BMD is increased with intermittent treatment but not present with chronic sustained elevations of PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. Multiple cellular pathways in the osteoblast are activated by PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. Target genes induced by intermittent PTH include IGF-I, amphiregulin, 1, alpha hydroxylase, Runx2, TGF-beta, RANKL, and M-CSF, while sclerostin, an inhibitor of the Wnt signaling pathway, is suppressed by treatment with PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/3,15-18\">",
"     3,15-18",
"    </a>",
"    ]. Activation of these pathways results in osteoblastic recruitment to the remodeling unit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By histomorphometry, patients treated with PTH have increased bone formation rates on cancellous, endocortical, and periosteal surfaces compared with untreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/19\">",
"     19",
"    </a>",
"    ]. Enhanced mineralization and greater numbers of both osteoblasts and osteoclasts have also been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]. Osteoblast number increases because of enhanced recruitment and differentiation of preosteoblasts. A reduction in programmed cell death (apoptosis) has been reported in some [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/13,21\">",
"     13,21",
"    </a>",
"    ], but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/19\">",
"     19",
"    </a>",
"    ]. Activation of osteoclasts occurs secondarily as a result of osteoblast recruitment. The effects of PTH are dose-dependent, such that higher daily doses result in greater increases in formation, and subsequently higher BMD with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/7,22\">",
"     7,22",
"    </a>",
"    ]. During the first month of treatment, formation occurs distinct from remodeling sites and hence there is little osteoclast activation. Later, remodeling is stimulated, resulting in increased bone formation and resorption.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Distinct skeletal compartments",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the introduction of high resolution imaging, it has been established that intermittent PTH treatment enhances trabecular more than cortical bone mass. In this compartment, trabecular thickness, number and connectivity are all increased by PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/23\">",
"     23",
"    </a>",
"    ]. Qualitative changes in trabecular micro architecture from patients treated with PTH are responsible for much of the improvement in the mechanical strength of the skeleton and its resistance to fracture (",
"    <a class=\"graphic graphic_figure graphicRef62933 \" href=\"UTD.htm?20/5/20562\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to the cortical compartment, periosteal circumference may increase with PTH treatment, but there is a decrease in secondary mineralization in the cortical skeleton [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Hence, BMD in highly trabecular sites like the vertebrae, are markedly increased by PTH, while bone in largely cortical regions, such as the radius, show either no change or a decrease in areal BMD within the first year of treatment.",
"   </p>",
"   <p>",
"    In summary, PTH treatment targets osteoblasts to enhance bone remodeling. Increases in bone formation occur more quickly than bone resorption, leading to an increase in lumbar BMD that is greater in the first two years of treatment than any antiresorptive agent. The actions of PTH on skeletal compartments are site-specific. Areal bone mass measurements by DXA capture only a small proportion of these qualitative effects which are important for skeletal integrity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PTH EFFECT ON BMD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     PTH monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, PTH is an anabolic therapy and results in significant increases in bone mineral density and a reduction in fracture risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     PTH 1-34",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Fracture Prevention Trial of PTH 1-34 (teriparatide) supports its efficacy in the treatment of osteoporosis. In this study, 1637 postmenopausal women with previous vertebral fractures were randomly assigned to receive PTH (20 or 40",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    subcutaneously) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"     10",
"    </a>",
"    ]. After 18 months of treatment the following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 20 mcg group, when compared to placebo, BMD increased by 9 and 3 more percentage points in the lumbar spine and femoral neck, respectively.",
"     </li>",
"     <li>",
"      In the 40 mcg group, when compared to placebo, BMD increased by 13 and 6 more percentage points in the lumbar spine and femoral neck, respectively.",
"     </li>",
"     <li>",
"      The beneficial effects of PTH were largely independent of age, baseline bone mineral density, and prevalent vertebral fractures.",
"     </li>",
"     <li>",
"      The main adverse effects of PTH were nausea, headache, and hypercalcemia, occurring more commonly at the higher dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A smaller study noted an increase of 13.5 percent in spine BMD and approximately 3 percent in femoral neck BMD after 18 months of PTH at doses of approximately 40",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, another study showed that after 11 months of PTH 1-34, 20",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    there was a 6 percent increase in spine BMD and a 1.5 percent increase in femoral neck BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/27\">",
"     27",
"    </a>",
"    ]. Radial BMD declines slightly in the first two years of PTH treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/5,6,12\">",
"     5,6,12",
"    </a>",
"    ]. In one report, higher baseline and greater short-term increases in bone turnover markers were associated with greater one-year increases in DXA of the hip and spine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recombinant PTH is also effective in men with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of osteoporosis in men\", section on 'Parathyroid hormone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     PTH 1-84",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH 1-84 is also effective for the treatment of osteoporosis in postmenopausal women as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Treatment of Osteoporosis with Parathyroid Hormone (TOP) study, 2532 postmenopausal women with or without prior vertebral fractures were randomly assigned to 100 mcg of PTH 1-84 or placebo daily by subcutaneous injection [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/29\">",
"       29",
"      </a>",
"      ]. Women receiving 100",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      (equivalent to approximately 40",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      of PTH 1-34) for 18 months had greater increases in lumbar spine and femoral neck BMD compared with placebo (6.9 and 2.5 percent, respectively). Volumetric trabecular BMD measured by quantitative computed tomography [QCT] at L3 and at the hip increased by 37 and 4.7 percent more, respectively, in the PTH group than in the placebo group.",
"     </li>",
"     <li>",
"      In another study using 100",
"      <span class=\"nowrap\">",
"       mcg/day,",
"      </span>",
"      PTH increased spine BMD in postmenopausal women by 6 percent in the first year, while there was virtually no change in hip BMD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study demonstrated a 6.3 percent increase in lumbar BMD of postmenopausal women treated for one year with 100",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      of PTH 1-84 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/4\">",
"       4",
"      </a>",
"      ]. Measurements of trabecular BMD by volumetric QCT revealed a 30 percent increase in spine volumetric BMD and an approximate 10 percent increase in femoral neck volumetric BMD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/4\">",
"       4",
"      </a>",
"      ]. However, there was a wide range of change in trabecular BMD from baseline, ie, from -15 percent to +132 percent, suggesting significant heterogeneity in patient responsiveness.",
"     </li>",
"     <li>",
"      The main adverse effects of PTH 1-84 were hypercalcemia, hypercalciuria, nausea, and headache.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar to the teriparatide study noted above, in a trial of PTH 1-84, greater one- and three-month increases in markers of bone turnover, in particular, a bone formation marker (serum N-propeptide of type 1 collagen [PINP]), were associated with greater increases in areal BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, PTH increases spine and hip BMD in a dose-dependent manner. But, relative percent change in BMD per individual may vary considerably for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is significant heterogeneity in skeletal responsiveness for a given subject treated with PTH.",
"     </li>",
"     <li>",
"      Skeletal sites differ in their response to PTH due to inherent remodeling activity.",
"     </li>",
"     <li>",
"      The type and biologic activity of PTH in clinical trials differ; some trials used teriparatide (PTH 1-34), others used a commercial preparation of PTH 1-84, still others made their own preparation of PTH [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PTH EFFECT ON FRACTURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to improvements in BMD, PTH reduces fracture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10,12,29,34\">",
"     10,12,29,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Fracture Prevention Trial (FPT), 1600 women with prior vertebral fractures receiving PTH 1-34 (20 mcg or 40",
"      <span class=\"nowrap\">",
"       mcg/day)",
"      </span>",
"      or placebo, there was significant vertebral and non-vertebral fracture efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"       10",
"      </a>",
"      ]. However, fracture risk reduction did not differ by dose, even though BMD changes were significantly greater with 40",
"      <span class=\"nowrap\">",
"       mcg/day.",
"      </span>",
"      The relative risks for vertebral fractures for the 20 and 40 mcg doses compared with placebo were 0.35 (95% CI 0.22-0.55) and 0.31 (95% CI 0.19-0.50) and for non-vertebral fractures the relative risks were 0.47 and 0.46, respectively (95% CI, 0.25-0.88 and 0.25-0.861). Unlike",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      trials, there were too few hip fractures over 21 months to conclude whether anti-fracture efficacy was also apparent for this type of catastrophic fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the TOP trial, 2532 postmenopausal women with or without prior vertebral fractures were randomly assigned to 100 mcg of PTH 1-84 or placebo daily by subcutaneous injection [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/29\">",
"       29",
"      </a>",
"      ]. Fewer women in the PTH group had a new or worsening vertebral fracture (RR 0.42, 95% CI 0.24-0.72) compared with the placebo group. PTH 1-84 prevented the first vertebral fracture in women without a prior vertebral fracture at baseline (RR 0.32, 95% CI 0.14-0.75) and reduced the risk of additional vertebral fractures in women with a history of vertebral fracture (RR 0.47, 95% CI 0.23-0.98). In contrast to FPT, there was no effect on non-vertebral fractures at any site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When comparing these two large trials, there were two obvious differences:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The FPT recruited slightly older women compared to TOP (mean age 69 versus 64 years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Entry criteria for the FPT included previous vertebral fracture (mean 2.3 vertebral fractures in each group) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"       10",
"      </a>",
"      ] whereas in TOP, 81 percent of the postmenopausal women had never suffered a vertebral fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, PTH treatment for at least 18 months markedly reduces the risk of spine fractures in postmenopausal women with osteoporosis. The risk reduction becomes apparent after eight months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"     10",
"    </a>",
"    ], and the effect is not dose dependent nor does it depend upon the type of PTH. However, non-vertebral fracture efficacy has only been established for teriparatide (PTH 1-34).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mechanisms of fracture reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have demonstrated that, during the course of antiresorptive therapy with estrogen or bisphosphonates, the proportionate change in BMD is much less than the fracture risk reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/37\">",
"     37",
"    </a>",
"    ]. Similar observations have been made with PTH therapy.",
"   </p>",
"   <p>",
"    In the Fracture Prevention Trial described above, PTH administration decreased vertebral fracture rates by 65 to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"     10",
"    </a>",
"    ]. A follow-up analysis calculated that the percentage of vertebral fracture reduction that could be attributed to the improvement in spine BMD was only 30 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The non-BMD determinants of bone strength that may explain the remaining benefit could include changes in bone geometry, microarchitecture, remodeling rate, damage accumulation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     collagen/mineral",
"    </span>",
"    matrix properties. The relative role of these factors in fracture risk reduction is not known. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanisms of action'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Back pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second meta-analysis of five trials revealed that patients receiving teriparatide therapy have a lower risk of new or worsening back pain compared to patients receiving placebo, estrogen, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/39\">",
"     39",
"    </a>",
"    ]. In some of the individual trials included in the analysis, the reduced risk of back pain appeared to correlate with a reduction in the risk of new painful vertebral fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fracture healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal studies, teriparatide enhanced callus formation and mechanical strength of fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/40\">",
"     40",
"    </a>",
"    ]. However, in randomized trials in humans, the results are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. As an example, in a randomized trial of teriparatide (20 or 40 mcg) or placebo in postmenopausal women with distal radial fractures, teriparatide did not significantly accelerate fracture repair compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/41\">",
"     41",
"    </a>",
"    ]. In contrast, a randomized trial of PTH 1-84 (100 mcg once daily) in women with pelvic fractures showed acceleration of fracture healing in those who received PTH 1-84 compared with those who did not (mean time to fracture healing 7.8 versus 12.6 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/42\">",
"     42",
"    </a>",
"    ]. The difference in results may be related to differences in study design, including site of fracture. More evidence from randomized trials is needed to know if teriparatide accelerates or induces fracture repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COMBINATION THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     PTH plus bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because PTH stimulates bone formation and bisphosphonates reduce bone resorption, it has been hypothesized that combining the two therapies would increase bone density more than either therapy alone. However, several trials have reported that PTH plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (either started concurrently or six months prior to PTH) resulted in no additional benefit for spine or hip BMD compared with PTH alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/4,5,43\">",
"     4,5,43",
"    </a>",
"    ]. This was illustrated in a trial of 238 treatment naive postmenopausal women with low bone density who were randomly assigned to receive PTH 1-84 (100 mcg sc daily), alendronate (10",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or both for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/4\">",
"     4",
"    </a>",
"    ]. All subjects received calcium (500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and vitamin D (400 int.",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    supplementation. After one year of therapy, results were as follows (",
"    <a class=\"graphic graphic_figure graphicRef78380 \" href=\"UTD.htm?35/1/35869\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone mineral density at the spine improved in all groups, but there was no difference between the PTH and the combination-therapy group.",
"     </li>",
"     <li>",
"      The volumetric density of trabecular bone in the spine (measured by quantitative CT) increased in all groups, but the increase in the PTH group was twice that in the other groups (",
"      <a class=\"graphic graphic_figure graphicRef78380 \" href=\"UTD.htm?35/1/35869\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Biochemical markers of bone resorption decreased in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      and the combination-therapy group but not in the PTH group.",
"     </li>",
"     <li>",
"      Biochemical markers of bone formation increased in the PTH group, but not in the combination-therapy group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in previously untreated patients, the effects of PTH are not additive to those of a bisphosphonate. These observations appear to result from the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    to impair PTH-induced stimulation of new bone formation. Thus, we do",
"    <strong>",
"     not",
"    </strong>",
"    suggest combination PTH and bisphosphonate therapy for osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     PTH after bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH is a treatment option in patients who cannot tolerate or who fail bisphosphonate therapy. PTH (teriparatide) increases BMD in women previously treated with bisphosphonates, although the improvement may be less than in women not previously exposed to bisphosphonates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/44\">",
"     44",
"    </a>",
"    ]. There are no data to suggest that this blunting would reduce fracture efficacy.",
"   </p>",
"   <p>",
"    In patients who have received prior therapy with bisphosphonates, it is unclear whether teriparatide should be added to or replace bisphosphonates. One trial compared the effects of adding versus switching to teriparatide in postmenopausal women who had received at least 18 months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/45\">",
"     45",
"    </a>",
"    ]. After 18 months of follow-up, the improvements in BMD at the lumbar spine (8.4 versus 4.8 percent) and total hip (3.2 versus 0.9 percent) were significantly greater in the group that added teriparatide. Changes in femoral neck BMD were not significantly different. The trial was not powered to assess fracture outcomes. Longer term follow-up after completion of the recommended course of teriparatide is not available.",
"   </p>",
"   <p>",
"    Given the absence of fracture and long-term follow-up data, and the additional cost and side effects of taking two agents, we suggest switching to rather than adding teriparatide in patients who have received bisphosphonates but require additional therapy for osteoporosis. There are no data to suggest that discontinuing long-term bisphosphonates requires a latent period before starting PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of bisphosphonate therapy after completing a course of PTH are discussed below. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'After PTH'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     PTH plus SERMs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior or concurrent treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    does not appear to compromise the effect of teriparatide on BMD and markers of bone turnover as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study of 59 postmenopausal women who had been taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      and then discontinued the antiresorptives and took teriparatide for 18 months, spine BMD increased more in the group that had previously taken raloxifene than in the group that had previously taken alendronate (10.2 versus 4.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/48\">",
"       48",
"      </a>",
"      ]. In addition, markers of bone turnover increased later and peaked lower in the group that had taken alendronate.",
"     </li>",
"     <li>",
"      In a six-month trial comparing teriparatide plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      to teriparatide plus placebo in 137 postmenopausal women with previously untreated osteoporosis, the increase in total hip BMD was greater in the combination group (2.3 versus 0.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/49\">",
"       49",
"      </a>",
"      ]. Spine BMD increased similarly the two groups (5.2 versus 6.2 percent).",
"     </li>",
"     <li>",
"      In another trial, 42 postmenopausal women who were previously treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      were randomly assigned to continue raloxifene alone or to continue raloxifene and add teriparatide [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/50\">",
"       50",
"      </a>",
"      ]. After 12 months of combined raloxifene and teriparatide, BMD increased in the spine, total hip, and trochanter (9.6, 2.7, and 3.6 percent, respectively), but there were no changes at any site in the raloxifene group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    (prior to or concurrent with teriparatide) does not suppress BMD response as much as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    . In patients who are taking raloxifene but require additional therapy, it is unclear whether teriparatide should be added to or replace raloxifene. In one trial, postmenopausal women taking raloxifene were randomly assigned to add or to switch to teriparatide. After 18 months, there were no significant differences in lumbar spine, total hip, or femoral neck BMD between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/45\">",
"     45",
"    </a>",
"    ]. The trial was not powered to assess fracture outcomes.",
"   </p>",
"   <p>",
"    We do not recommend combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    and teriparatide. However, in patients not adequately treated with raloxifene, there is no need to delay teriparatide therapy once raloxifene is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     PTH plus hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined estrogen plus PTH therapy appears to be more effective than hormone therapy alone. In one trial of 34 postmenopausal women randomly assigned to receive hormone therapy (estrogen-progestin) alone, or combined with PTH 1-34 (25",
"    <span class=\"nowrap\">",
"     mcg/day)",
"    </span>",
"    for 36 months, those receiving combination therapy had a greater increase in spine and hip BMD (13 and 2.7 percent, respectively) than those receiving hormone therapy alone (no change seen at either site) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/12\">",
"     12",
"    </a>",
"    ]. A slightly larger study reported similar increases in spine BMD with the same dose of PTH combined with hormone therapy, although hip BMD actually increased more (ie, 4.4 percent) than the earlier study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/51\">",
"     51",
"    </a>",
"    ]. A third trial reported similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     AFTER PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH 1-34 (teriparatide) is the only form of PTH currently available for the treatment of postmenopausal or male osteoporosis. Due to the potential risk of carcinogenicity, PTH treatment should be limited to those most severely affected and for a maximum of two years. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Adverse events'",
"    </a>",
"    below.) The trials of fracture efficacy only lasted 18 to 21 months (TOP [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/29\">",
"     29",
"    </a>",
"    ] and FPT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"     10",
"    </a>",
"    ], respectively). However, this raises significant uncertainty about choices for therapy after stopping teriparatide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Fracture risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an open label extension of the Fracture Prevention Trial (FPT), women were followed for an additional 18 months after discontinuation of teriparatide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/53\">",
"     53",
"    </a>",
"    ]. Women who were initially randomized to teriparatide still had a 40 percent relative risk reduction in vertebral fractures during the follow up 18-month period, compared with those who had received placebo during the FPT, even though more women in the former placebo group used anti-resorptives in the open label extension when compared with the former teriparatide group. A small decrease in BMD was noted in the follow up of the FPT, despite the persistent reduction in fracture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have reported that the gains in hip and spine BMD with PTH decline following PTH discontinuation. In the PaTH trial, which was a randomized two-year study with one year of PTH 1-84 with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , followed by alendronate or placebo, women on placebo after 12 months of PTH lost nearly 2 percent of their spine BMD over the subsequent 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/4,54\">",
"     4,54",
"    </a>",
"    ]. Loss of trabecular volumetric BMD (as measured by quantitative CT) was more striking (17 percent) (",
"    <a class=\"graphic graphic_figure graphicRef51014 \" href=\"UTD.htm?9/56/10126\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Antiresorptive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with an antiresorptive agent after PTH preserves the gains in BMD achieved with PTH. This is illustrated by findings from the PaTH trial described above. Women randomized to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    following PTH discontinuation had a further increase in areal BMD of nearly 6 percent, coupled with a 6 percent increase during the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/54\">",
"     54",
"    </a>",
"    ]. Treatment with alendronate during that year following PTH 1-84, preserved the increase of 30 percent in trabecular BMD gained in the first year by PTH 1-84 alone (",
"    <a class=\"graphic graphic_figure graphicRef51014 \" href=\"UTD.htm?9/56/10126\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were reported in studies using estrogen or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    after PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who had a nearly 30 percent increase in areal BMD with PTH lost &lt;4 percent of that rise when PTH was discontinued and estrogen therapy was continued [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the European Study of Forsteo (EUROFORS), women who had received one year of teriparatide were randomly assigned for a second year to continue teriparatide or to switch to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/57\">",
"       57",
"      </a>",
"      ]. BMD in the women who received teriparatide for a second year continued to increase, whereas BMD was maintained in the women who received raloxifene and decreased in women who received placebo. The overall changes in lumbar spine BMD in the three groups from baseline to 24 months were 10.7, 7.8, and 3.8 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, after PTH treatment is discontinued, an antiresorptive, preferably a bisphosphonate, should be used to preserve or increase gains in BMD acquired with PTH alone.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    is an alternative for women who are unable to tolerate oral or intravenous bisphosphonates. A persistent reduction in fracture risk with the use of antiresorptive therapy after PTH is discontinued has not yet been firmly established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Retreatment with PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH results in significant increases in bone mineral density and a reduction in fracture risk. However, due to the potential risk of carcinogenicity, teriparatide treatment should be limited to a maximum of two years. Nevertheless, there is interest in studying the efficacy of retreatment with teriparatide, after a drug-free interval, to determine if the initial response can be replicated. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a planned extension of a randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/5\">",
"       5",
"      </a>",
"      ] comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      , teriparatide (37 micrograms daily), or both, retreatment with daily teriparatide (average dose 30 micrograms) after a 12-month hiatus in the subgroup who had received 24 months of teriparatide, resulted in an increase in lumbar spine BMD. However, the increment was smaller than during the initial 12 months of teriparatide therapy (5.2 versus 12.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/58\">",
"       58",
"      </a>",
"      ]. Femoral neck BMD did not change during retreatment with teriparatide.",
"     </li>",
"     <li>",
"      In an observational study following a trial of intermittent administration of teriparatide for 15 months, ie, once daily for three months, followed by three months off and then a return to three months daily, in postmenopausal women treated with long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      , retreatment with daily teriparatide (25 micrograms daily for 15 months), after a 12-month interval taking alendronate alone, resulted in significant increases (4.7 to 4.9 percent) in lumbar spine BMD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, retreatment with teriparatide does appear to increase spine BMD, but the increase is less than that of initial treatment. We do not recommend retreatment with teriparatide, particularly in patients who have already received a two-year course, owing to the lack of safety data with longer-term therapy. It is unknown if intermittent administration (to reach a cumulative 24-month course) is more or less efficacious than the administration of teriparatide for 24 months consecutively. Until such data is available, we do not recommend long-term intermittent therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Short-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, both teriparatide (PTH 1-34) and PTH 1-84 are well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/4,5,10,30\">",
"     4,5,10,30",
"    </a>",
"    ]. Hypercalcemia and hypercalciuria are the two most common side effects of both types of PTH treatment. A single teriparatide injection raises PTH 1-34 levels 10-fold above baseline, but these return to baseline within four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one trial, 11 percent of women receiving teriparatide (20 mcg) had an elevated serum calcium concentration from samples obtained at one time point; with retesting, only 3 percent had persistent hypercalcemia requiring dose reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"     10",
"    </a>",
"    ]. Hypercalcemia was more common with the 40 mcg dose (which is not currently approved or available). Although hypercalciuria can be detected with teriparatide use, the urinary",
"    <span class=\"nowrap\">",
"     calcium/creatinine",
"    </span>",
"    ratio rarely exceeds 0.4, and there are no reported cases of nephrocalcinosis associated with teriparatide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. However, PTH should probably not be used in individuals with a history of renal stones or persistent hypercalcuria. Hypercalcemia appears to be more common with PTH 1-84 (ie, closer to 10 percent of subjects after retesting), although the mechanism responsible for this difference between PTHs is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasional hypotension or tachycardia can occur with the first few doses. Nausea and headache are reported among individuals treated with teriparatide but these do not appear to be significantly different from placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"     10",
"    </a>",
"    ]. Debilitating muscle cramps have also been reported following PTH treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/60\">",
"     60",
"    </a>",
"    ]. There was a higher frequency of nausea and vomiting in women receiving PTH 1-84 versus placebo in the TOP trial but this could be related to a greater frequency of hypercalcemia in that study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum uric acid increases with teriparatide and 1-84 PTH, and in some subjects may precipitate an attack of gout. Patients with uric acid levels greater than 7.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    probably should not be treated with PTH until their uric acid is controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, short term side effects from PTH are relatively mild except for occasional idiosyncratic responses; rarely does significant hypercalcemia (ie, serum calcium greater than 11.0",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    occur. Algorithms have been devised to adjust PTH treatment (ie, alternate day therapy) in light of persistent hypercalcemia. Generally, a reduction in calcium supplementation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temporary cessation of vitamin D treatment leads to resolution of hypercalcemia. Persistent hypercalcemia after discontinuation of PTH should lead to an evaluation for other secondary causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;In practice, very few long-term side effects have been reported with PTH. Anecdotally, investigators have reported improvement in back pain with teriparatide therapy, but it is unclear whether this is a function of fewer fractures, or a true analgesic response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"     10",
"    </a>",
"    ]. The most theoretically worrisome adverse event is the development of osteosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/61\">",
"     61",
"    </a>",
"    ]. Of more than 300,000 patients worldwide treated with teriparatide, there has been one reported case of osteosarcoma in a postmenopausal women taking teriparatide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/62\">",
"     62",
"    </a>",
"    ]. Causality between teriparatide and the osteosarcoma could not be established in this patient. Furthermore, in an interim report from the Osteosarcoma Surveillance Study, there were 1448 cases of osteosarcoma diagnosed in the United States between 2003 and 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/63\">",
"     63",
"    </a>",
"    ]. Among the 549 osteosarcoma patients who were interviewed thus far, none reported a history of teriparatide use.",
"   </p>",
"   <p>",
"    However, a high proportion of Fischer rats administered PTH 1-34 from infancy through senescence (ie, eight weeks to two years) developed osteosarcoma at doses that were in the range of 30 to 4500",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    for humans [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/61\">",
"     61",
"    </a>",
"    ]. Clearly higher doses for long duration were major risks for development of osteosarcoma in rats. It should be noted there are several case reports of coexistent osteosarcoma in patients who have primary hyperparathyroidism. Although outside groups have studied the potential risk for osteosarcoma in humans, and concluded there was minimal risk, the FDA contends that PTH therapy be limited to two years, pending further post-marketing studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO DAILY INJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH treatment requires daily injection and is expensive. In one analysis, daily PTH therapy, when compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , was less cost-effective as a first-line drug for severe osteoporosis in women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/65\">",
"     65",
"    </a>",
"    ]. Hence alternative approaches have been considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Intermittent PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;One randomized trial reported that intermittent administration of teriparatide for 15 months, ie, once daily injection for three months, followed by three months off and then a return to three months daily, in postmenopausal women treated with long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , was as effective for increasing BMD as daily teriparatide and alendronate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/66\">",
"     66",
"    </a>",
"    ]. More studies are currently planned to investigate whether even shorter courses intermittently can be as effective as daily treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     PTH once weekly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another randomized trial showed that once weekly teriparatide, administered by injection to postmenopausal women with fractures at doses of 60",
"    <span class=\"nowrap\">",
"     mcg/dose/week,",
"    </span>",
"    was as good as daily teriparatide with respect to changes in spine BMD (ie, an approximate 6 to 8 percent increase over baseline after 48 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, in a trial of 50 postmenopausal women randomly assigned to 100 micrograms of PTH 1-84 (equivalent to approximately 40",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    of PTH 1-34) administered daily for one month and then weekly for 11 months, weekly PTH improved lumbar spine BMD compared with placebo (2.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/68\">",
"     68",
"    </a>",
"    ]. Additional studies are required to determine the optimal frequency of PTH administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Acute stimulation of endogenous PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcilytic agents (calcium sensing receptor antagonists) that trick the calcium sensing receptor into a state in which it perceives low serum calcium requiring stimulation of endogenous PTH secretion are clinical alternatives to administration of PHT. Phase I and Ib trials have been completed. Use of these antagonists results in a rapid increase in PTH secretion, which returns to baseline within several hours. However, further studies with these agents have not progressed, and it is uncertain if these agents can substitute as oral drugs that mimic intermittently administered subcutaneous PTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Transdermal administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal delivery of PTH is an appealing alternative to daily injection. The efficacy of a transdermal delivery system was evaluated in a phase II clinical trial comparing transdermal teriparatide (20, 30, or 40 mcg daily) to a placebo patch or teriparatide injection (20 mcg daily) in 165 postmenopausal women with osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/69\">",
"     69",
"    </a>",
"    ]. After six months, the mean change in lumbar spine BMD was significantly greater than placebo and similar in all active treatment groups (3 to 5 percent increase versus no change with placebo).",
"   </p>",
"   <p>",
"    With the transdermal system (all doses), there was a rapid rise in plasma teriparatide concentration combined with a rapid fall-off, a pattern that is required for an anabolic rather than catabolic effect of PTH. In addition, the transdermal system resulted in a higher peak concentration and a shorter half-life of plasma teriparatide than the injection, a finding that may signal a greater anabolic effect.",
"   </p>",
"   <p>",
"    The transdermal system is an adhesive patch with 1300 teriparatide coated microneedles. It was well tolerated with few reports of pinpoint bleeding or bruising at the site of administration, although transient erythema was common. Transient hypercalcemia occurred in 8 to 24 percent of teriparatide-treated subjects compared with 3 percent in the placebo group. In all but three subjects, serum calcium returned to normal spontaneously or after discontinuation of calcium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin D supplements (per protocol). In three subjects, calcium returned to normal after study medication was temporarily withheld, and there was no recurrence after restarting treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     OTHER POSSIBLE USES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Glucocorticoid-induced osteoporosis (GIO)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bisphosphonates are considered standard therapy to prevent or treat GIO [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/70\">",
"     70",
"    </a>",
"    ]. However, PTH is also effective, and teriparatide has been approved for the treatment of GIO. The role of PTH in the treatment of GIO is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H14#H14\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Parathyroid hormone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is one trial using PTH in premenopausal women receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26580?source=see_link\">",
"     nafarelin",
"    </a>",
"    for endometriosis. Those women who received teriparatide, 40",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    had a 2.1 percent increase in lumbar BMD compared with a nearly 5 percent loss in those receiving placebo plus nafarelin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/71\">",
"     71",
"    </a>",
"    ]. At the current time, teriparatide is not approved for the treatment of low bone mass in premenopausal women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Male osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three trials using PTH in men with osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/5,6,72\">",
"     5,6,72",
"    </a>",
"    ]. All show that teriparatide can increase spine and hip BMD in doses of 20 to 40",
"    <span class=\"nowrap\">",
"     mcg/day.",
"    </span>",
"    There are no trials for fracture outcome in men, but teriparatide is approved for the treatment of this condition in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Primary hypoparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hypoparathyroidism is difficult to treat whether it is primary (ie, autoimmune), or secondary to surgery, radiation, or other causes. The current regimens include multiple combinations of calcitriol, calcium, magnesium, and sometimes vitamin D2 and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    . However, tetany can develop quickly, and often these patients require very large doses of calcium (&gt;3",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    One randomized trial showed that 20 mcg of PTH given twice daily was as safe and as effective as multiple dosing with calcium and vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/73\">",
"     73",
"    </a>",
"    ]. Currently, teriparatide is not approved for the treatment of hypoparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of hypocalcemia\", section on 'Hypoparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12011562\">",
"    <span class=\"h2\">",
"     Periodontal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of teriparatide on alveolar bone loss associated with periodontal disease has also been tested. Severe periodontal disease, a major cause of tooth loss worldwide, is characterized by gingival inflammation and loss of supportive connective tissues, including alveolar bone. In one trial, 40 adults with chronic periodontitis who had periodontal surgery were randomly assigned to receive teriparatide (20 mcg) or placebo daily for six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/74\">",
"     74",
"    </a>",
"    ]. After one year, radiographic resolution of periodontal bone defects in the teriparatide group was significantly greater than that in the placebo group (mean linear gain in bone 1.86 versus 0.16 mm). There was also significant improvement in some clinical parameters, including probing depth and clinical attachment level. Until larger and longer trials with additional clinical (eg, reduction in tooth loss) and safety endpoints are available, we do not recommend teriparatide for the treatment of chronic periodontitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18777?source=see_link&amp;anchor=H12#H12\">",
"     \"Gingivitis and periodontitis in adults: Classification and dental treatment\", section on 'Periodontitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     MANAGEMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential candidates for PTH therapy include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/1,75,76\">",
"     1,75,76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men or postmenopausal women with severe osteoporosis (T-score of -3.5 or below even in the absence of fractures; T-score of -2.5 or below plus a fragility fracture)",
"     </li>",
"     <li>",
"      Patients with osteoporosis who are unable to tolerate bisphosphonates or who have relative contraindications to bisphosphonates (achalasia, scleroderma esophagus, esophageal strictures)",
"     </li>",
"     <li>",
"      Patients who fail other osteoporosis therapies (fracture with loss of BMD in spite of compliance with therapy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given its cost, subcutaneous route of administration, long-term safety concerns, and availability of other agents, PTH is generally not used as a first-line drug for treatment or prevention of osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a pretreatment DXA, pretreatment evaluation should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum Ca, P, creatinine, alkaline phosphatase, albumin, 25-hydroxyvitamin D, uric acid",
"     </li>",
"     <li>",
"      24-hour urine Ca, creatinine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are vitamin D deficient should be replaced with vitamin D prior to starting PTH therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .) If baseline hypercalcemia or hypercalciuria are present, further evaluation for primary hyperparathyroidism is necessary. PTH therapy should not be started unless hypercalciuria is resolved. If the uric acid pre-treatment is &gt;7.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (446",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    or if there is a history of gout, PTH probably should not be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with vascular insufficiency, or orthostatic hypotension, pulse and blood pressure should be monitored carefully following the first PTH injection.",
"     </li>",
"     <li>",
"      There are no guidelines for when to measure calcium, although in the clinical trials, it is usually assessed at several time points including baseline, 1, 6 and 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/26/15786/abstract/4,64\">",
"       4,64",
"      </a>",
"      ]. However, there is wide variation in clinical practice for timing of follow-up serum calcium levels, from none to once every three months. In any case, serum calcium should only be drawn 24 hours after the last PTH injection.",
"     </li>",
"     <li>",
"      Uric acid should be monitored at baseline and at six months.",
"     </li>",
"     <li>",
"      Frequency of BMD measurements is subjective, but most investigators would not consider a follow up BMD for at least one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with primary or secondary hyperparathyroidism should not receive PTH, even if they have low BMD.",
"     </li>",
"     <li>",
"      Patients who are at increased baseline risk for osteosarcoma, such as those with Paget disease of bone, history of prior radiation therapy, or unexplained elevation of alkaline phosphatase, should not receive PTH.",
"     </li>",
"     <li>",
"      In patients with pre-existing malignancies, renal stones, gout, or renal insufficiency, PTH should not be considered unless other drugs have failed, and the benefits of PTH outweigh potential risks.",
"     </li>",
"     <li>",
"      Caution about calcium supplementation is warranted although clinical trials have used at least 500 mg elemental calcium and at least 400 int. units of vitamin D per day. Dose reductions are feasible if modest hypercalcemia occurs, although the first step should be to discontinue all calcium and vitamin D, and repeat the serum calcium 24 hours after the last dose of PTH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH is an effective anti-osteoporosis drug that increases bone mineral density and reduces fracture risk. Given its cost, subcutaneous route of administration, long-term safety concerns, and availability of other agents, PTH is generally not used as a first-line drug for treatment or prevention of osteoporosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In men and women with severe osteoporosis (low bone mineral density [T score &lt;-2.5] and at least one fragility fracture) who continue to fracture after one year of bisphosphonate therapy, we suggest human recombinant PTH therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'PTH effect on fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also suggest PTH therapy for patients with severe osteoporosis who are unable to tolerate any of the available bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other candidates for parathyroid hormone include patients who have relative contraindications to bisphosphonates (achalasia, scleroderma esophagus, esophageal strictures).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Previous or current bisphosphonate use, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      , \"blunts\" the response to PTH. However there are no data to suggest that discontinuing long-term bisphosphonate therapy requires a latency period before starting PTH. Thus, in patients who are switching from bisphosphonates to PTH, we suggest starting PTH immediately after bisphosphonates are discontinued (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring patients on PTH treatment should include measurement of serum calcium, renal function and uric acid prior to initiation of therapy and at least once during their course. Monitoring of bone mineral density is reviewed separately. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Monitoring'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest stopping PTH treatment after a maximum of 24 months, because of concerns about osteosarcomas which have been observed in rats receiving high doses of PTH (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This complication has rarely been observed in human subjects, and there is no direct evidence linking the development of osteosarcoma to dose or duration of teriparatide.",
"     </li>",
"     <li>",
"      For patients at high risk for subsequent fracture after discontinuing PTH, we suggest starting a bisphosphonate after PTH is discontinued (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       Raloxifene",
"      </a>",
"      is an alternative for individuals who are intolerant of the available bisphosphonates. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'After PTH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/1\">",
"      Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/2\">",
"      Rosen CJ, Bilezikian JP. Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001; 86:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/3\">",
"      Rosen CJ. The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gene Expr 2003; 13:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/4\">",
"      Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/5\">",
"      Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/6\">",
"      Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85:3069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/7\">",
"      Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005; 90:3970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/8\">",
"      Hodsman AB, Fraher LJ, Ostbye T, et al. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 1993; 91:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/9\">",
"      McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005; 165:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/10\">",
"      Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/11\">",
"      Rosen CJ, Ackert-Bicknell CL, Adamo ML, et al. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone 2004; 35:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/12\">",
"      Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/13\">",
"      Dobnig H, Stepan V, Leb G, et al. Recovery from severe osteoporosis following cure from ectopic ACTH syndrome caused by an appendix carcinoid. J Intern Med 1996; 239:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/14\">",
"      Krane SM. Identifying genes that regulate bone remodeling as potential therapeutic targets. J Exp Med 2005; 201:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/15\">",
"      Partridge AW, Liu S, Kim S, et al. Transmembrane domain helix packing stabilizes integrin alphaIIbbeta3 in the low affinity state. J Biol Chem 2005; 280:7294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/16\">",
"      Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 2004; 89:3332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/17\">",
"      Sowa H, Kaji H, Iu MF, et al. Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts. J Biol Chem 2003; 278:52240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/18\">",
"      Krishnan V, Moore TL, Ma YL, et al. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol Endocrinol 2003; 17:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/19\">",
"      Lindsay R, Zhou H, Cosman F, et al. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007; 22:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/20\">",
"      Hodsman AB, Kisiel M, Adachi JD, et al. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 2000; 27:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/21\">",
"      Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003; 278:50259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/22\">",
"      Sato M, Vahle J, Schmidt A, et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 2002; 143:3230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/23\">",
"      Jerome CP, Burr DB, Van Bibber T, et al. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 2001; 28:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/24\">",
"      Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003; 88:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/25\">",
"      Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/26\">",
"      Parfitt AM. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002; 17:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/27\">",
"      Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/28\">",
"      Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005; 20:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/29\">",
"      Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007; 146:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/30\">",
"      Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88:5212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/31\">",
"      Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000; 85:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/32\">",
"      Bauer DC, Garnero P, Bilezikian JP, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006; 91:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/33\">",
"      Lane NE, Sanchez S, Genant HK, et al. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2000; 11:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/34\">",
"      Bogado, CE, Zanchetta, JR, Mango, A, et al. Effects of Parathyroid Hormone 1-84 on Cortical and Trabecular Bone at the Hip as Assessed by QCT: Results at 18 months from the TOP Study. J Bone Miner Res 2005; 20:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/35\">",
"      Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/36\">",
"      McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/37\">",
"      Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/38\">",
"      Chen P, Miller PD, Delmas PD, et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006; 21:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/39\">",
"      Nevitt MC, Chen P, Dore RK, et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006; 17:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/40\">",
"      Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999; 14:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/41\">",
"      Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010; 25:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/42\">",
"      Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 2011; 93:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/43\">",
"      Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006; 91:2882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/44\">",
"      Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008; 23:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/45\">",
"      Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009; 94:3772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/46\">",
"      Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008; 93:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/47\">",
"      Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008; 93:3785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/48\">",
"      Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/49\">",
"      Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005; 20:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/50\">",
"      Cosman F, Nieves JW, Zion M, et al. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 2008; 19:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/51\">",
"      Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001; 16:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/52\">",
"      Roe, EB, Sanchez, SD, Cann, CE, et al. PTH-induced increases in bone density are preserved with estrogen: results from a follow-up year in postmenopausal osteoporosis. J Bone Miner Res 2000; 15:S193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/53\">",
"      Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/54\">",
"      Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005; 353:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/55\">",
"      Lane NE, Sanchez S, Modin GW, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000; 15:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/56\">",
"      Adami S, San Martin J, Mu&ntilde;oz-Torres M, et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 2008; 19:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/57\">",
"      Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 2009; 24:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/58\">",
"      Finkelstein JS, Wyland JJ, Leder BZ, et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 2009; 94:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/59\">",
"      Cosman F, Nieves JW, Zion M, et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 2009; 24:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/60\">",
"      Kakaria PJ, Nashel DJ, Nylen ES. Debilitating muscle cramps after teriparatide therapy. Ann Intern Med 2005; 142:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/61\">",
"      Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002; 30:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/62\">",
"      Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J Bone Miner Res 2007; 22:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/63\">",
"      Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 2012; 27:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/64\">",
"      Tashjian AH Jr, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002; 17:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/65\">",
"      Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006; 166:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/66\">",
"      Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005; 353:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/67\">",
"      Fujita T, Inoue T, Morii H, et al. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 1999; 9:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/68\">",
"      Black DM, Bouxsein ML, Palermo L, et al. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab 2008; 93:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/69\">",
"      Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010; 95:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/70\">",
"      Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001; 44:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/71\">",
"      Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 1998; 280:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/72\">",
"      Orwoll ES. Treatment of osteoporosis in men. Calcif Tissue Int 2004; 75:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/73\">",
"      Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003; 88:4214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/74\">",
"      Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 2010; 363:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/75\">",
"      Hodsman A, Scientific Advisory Council of Osteoporosis Canada, Papaioannou A, et al. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ 2006; 175:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/26/15786/abstract/76\">",
"      Cranney A, Papaioannou A, Zytaruk N, et al. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 2006; 175:52.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2057 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15786=[""].join("\n");
var outline_f15_26_15786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anabolic therapy for bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bone remodeling unit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anabolics versus antiresorptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Molecular and cellular level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Distinct skeletal compartments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PTH EFFECT ON BMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PTH monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - PTH 1-34",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - PTH 1-84",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PTH EFFECT ON FRACTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Risk reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mechanisms of fracture reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Back pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fracture healing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COMBINATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PTH plus bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PTH after bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PTH plus SERMs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PTH plus hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      AFTER PTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Fracture risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Antiresorptive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Retreatment with PTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Short-term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Long-term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ALTERNATIVES TO DAILY INJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Intermittent PTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PTH once weekly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Acute stimulation of endogenous PTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Transdermal administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      OTHER POSSIBLE USES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Glucocorticoid-induced osteoporosis (GIO)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Male osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Primary hypoparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12011562\">",
"      Periodontal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2057\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2057|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/48/24335\" title=\"figure 1\">",
"      Human parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/5/20562\" title=\"figure 2\">",
"      PTH effect skeletal architecture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/1/35869\" title=\"figure 3\">",
"      PTH alone or with alendronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/56/10126\" title=\"figure 4\">",
"      Alendronate after PTH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18777?source=related_link\">",
"      Gingivitis and periodontitis in adults: Classification and dental treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=related_link\">",
"      Parathyroid hormone secretion and action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_26_15787="AMDR";
var content_f15_26_15787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acceptable Macronutrient Distribution Range",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Carbohydrate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protein",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 year",
"       </td>",
"       <td>",
"        45-65",
"       </td>",
"       <td>",
"        5-20",
"       </td>",
"       <td>",
"        30-40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-18 year",
"       </td>",
"       <td>",
"        45-65",
"       </td>",
"       <td>",
"        10-30",
"       </td>",
"       <td>",
"        25-35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;18 year",
"       </td>",
"       <td>",
"        45-65",
"       </td>",
"       <td>",
"        10-35",
"       </td>",
"       <td>",
"        20-35",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Acceptable Macronutrient Distribution Range (AMDR) is the range of intake for a particular energy source, expressed as a percentage of total caloric intakes that is associated with reduced risk of chronic disease while providing intakes of essential nutrients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (2002/2005).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15787=[""].join("\n");
var outline_f15_26_15787=null;
var title_f15_26_15788="LN metastases in endometrial CA";
var content_f15_26_15788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of pelvic and para-aortic lymph node metastases in clinical stage I endometrial carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Histologic grade",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Depth of myometrial invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        None",
"       </td>",
"       <td class=\"subtitle2\">",
"        Inner third",
"       </td>",
"       <td class=\"subtitle2\">",
"        Middle third",
"       </td>",
"       <td class=\"subtitle2\">",
"        Outer third",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"4\">",
"        Percent pelvic lymph nodes involved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        288",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"4\">",
"        Percent para-aortic lymph nodes involved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        288",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Creasman WT, Morrow CP, Bundy BN, et al, Cancer 1987; 60(8 Suppl):2035.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15788=[""].join("\n");
var outline_f15_26_15788=null;
var title_f15_26_15789="Localization Horners syndrome";
var content_f15_26_15789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of Horner's syndrome in adults based on the location of the lesion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Central (1st order)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Hypothalamus",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Stroke",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Tumor",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Brainstem (lateral medulla)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Stroke",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Demyelination",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Tumor",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Spinal cord (cervico-thoracic)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Trauma",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Tumor (intramedullary)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Myelitis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Syringomyelia",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Demyelination",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Arteriovenous malformation",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Infarction",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Preganglionic (2nd order)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Pulmonary apical lesions",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Subclavian artery aneurysm",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Apical lung tumor (Pancoast tumor)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Mediastinal tumors",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Cervical rib",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Iatrogenic (jugular cannulation, chest tube placement, thoracic surgery)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Thyroid malignancies",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Postganglionic (3rd order)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Superior cervical ganglion",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Trauma",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Jugular venous ectasia",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Iatrogenic (surgical neck dissection)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Internal carotid artery",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Dissection",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Aneurysm",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Trauma",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Arteritis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Thrombosis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Tumor",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Skull base lesions",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           (nasopharyngeal carcinoma, lymphoma)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Cavernous sinus lesion",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Tumors",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Invasive pituitary tumor",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Inflammation",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Thrombosis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Carotid aneurysm",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Miscellaneous (cluster headache)",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15789=[""].join("\n");
var outline_f15_26_15789=null;
var title_f15_26_15790="Diagnostic algorithm CIS";
var content_f15_26_15790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for patients with typical clinically isolated syndromes (CIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 289px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This algorithm only applies to patients 14 to 50 years old with typical CIS and a complete diagnostic workup.",
"    <div class=\"footnotes\">",
"     BS: brainstem; DIS: dissemination in space; DIT: dissemination in time; Gd: gadolinium; JC: juxtacortical; PF: posterior fossa; PV: periventricular; SC: spinal cord.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Montalban X, Tintor M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010; 74:427. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15790=[""].join("\n");
var outline_f15_26_15790=null;
var title_f15_26_15791="Seborrheic keratosis PI";
var content_f15_26_15791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Seborrheic keratosis is a condition that causes small growths on the skin. The growths can look like something was stuck on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_26_15791=[""].join("\n");
var outline_f15_26_15791=null;
